{"640de65e9f09545c463bc419bffb7084fc40fae5": [], "PMC7397219": [], "PMC7121600": [["IntroductionThe common medical conditions encountered by the dentist in daily practice that necessitates extra knowledge include cardiac diseases, pulmonary diseases, hypertension, diabetes, bleeding disorders, pregnant patients, multiple drug interactions, infectious diseases, renal complications, diabetes, and patients undergoing radiation therapy [1].", [["cardiac", "ANATOMY", 129, 136], ["pulmonary", "ANATOMY", 147, 156], ["renal", "ANATOMY", 279, 284], ["cardiac diseases", "DISEASE", 129, 145], ["pulmonary diseases", "DISEASE", 147, 165], ["hypertension", "DISEASE", 167, 179], ["diabetes", "DISEASE", 181, 189], ["bleeding disorders", "DISEASE", 191, 209], ["infectious diseases", "DISEASE", 258, 277], ["renal complications", "DISEASE", 279, 298], ["diabetes", "DISEASE", 300, 308], ["cardiac", "ANATOMICAL_SYSTEM", 129, 136], ["pulmonary", "ORGAN", 147, 156], ["patients", "ORGANISM", 220, 228], ["renal", "ORGAN", 279, 284], ["patients", "ORGANISM", 314, 322], ["patients", "SPECIES", 220, 228], ["patients", "SPECIES", 314, 322], ["cardiac diseases", "PROBLEM", 129, 145], ["pulmonary diseases", "PROBLEM", 147, 165], ["hypertension", "PROBLEM", 167, 179], ["diabetes", "PROBLEM", 181, 189], ["bleeding disorders", "PROBLEM", 191, 209], ["multiple drug interactions", "PROBLEM", 230, 256], ["infectious diseases", "PROBLEM", 258, 277], ["renal complications", "PROBLEM", 279, 298], ["diabetes", "PROBLEM", 300, 308], ["radiation therapy", "TREATMENT", 334, 351], ["cardiac", "ANATOMY", 129, 136], ["diseases", "OBSERVATION", 137, 145], ["pulmonary", "ANATOMY", 147, 156], ["diseases", "OBSERVATION", 157, 165], ["hypertension", "OBSERVATION", 167, 179], ["renal", "ANATOMY", 279, 284], ["complications", "OBSERVATION", 285, 298]]], ["When treatment is carried out in a healthy individual, it is sufficient to concentrate on the technical part of the procedure, but when there is a need to treat patients with systemic illness who are under medical management, it is equally important to avoid any potential medical emergency or complication.IntroductionThe world is experiencing growth in the number and proportion of older persons in the population, because of this the incidence of a number of pathologies has been increasing and thus is producing an increase in the number of individuals with systemic medical conditions that can affect oral health and subsequent dental treatment.", [["oral", "ANATOMY", 606, 610], ["systemic illness", "DISEASE", 175, 191], ["patients", "ORGANISM", 161, 169], ["persons", "ORGANISM", 390, 397], ["oral", "ORGANISM_SUBDIVISION", 606, 610], ["patients", "SPECIES", 161, 169], ["persons", "SPECIES", 390, 397], ["treatment", "TREATMENT", 5, 14], ["the procedure", "TREATMENT", 112, 125], ["systemic illness", "PROBLEM", 175, 191], ["medical management", "TREATMENT", 206, 224], ["complication", "PROBLEM", 294, 306], ["pathologies", "PROBLEM", 462, 473], ["systemic medical conditions", "PROBLEM", 562, 589], ["subsequent dental treatment", "TREATMENT", 622, 649], ["growth", "OBSERVATION_MODIFIER", 345, 351], ["pathologies", "OBSERVATION", 462, 473], ["increasing", "OBSERVATION_MODIFIER", 483, 493], ["increase", "OBSERVATION_MODIFIER", 519, 527]]], ["The dental management of medically compromised patients can be sometimes problematic in terms of oral complications, dental therapy, and emergency care.", [["oral", "ANATOMY", 97, 101], ["patients", "ORGANISM", 47, 55], ["oral", "ORGANISM_SUBDIVISION", 97, 101], ["patients", "SPECIES", 47, 55], ["The dental management", "TREATMENT", 0, 21], ["oral complications", "PROBLEM", 97, 115], ["dental therapy", "TREATMENT", 117, 131], ["emergency care", "TREATMENT", 137, 151]]], ["One of the challenges faced by dental specialists today is the assessment and management of these patients.", [["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["the assessment", "TEST", 59, 73], ["management", "TREATMENT", 78, 88]]], ["10.1007/978-3-319-60997-3_11 geriatric patients are much more likely to be at least partially dentulous having a complex medical history and the use of multiple medications.IntroductionIn order to ascertain a patient\u2019s medical status, a thorough history taking is essential.", [["patients", "ORGANISM", 39, 47], ["patient", "ORGANISM", 209, 216], ["patients", "SPECIES", 39, 47], ["patient", "SPECIES", 209, 216], ["multiple medications", "TREATMENT", 152, 172]]], ["This chapter will focus on guidelines for endodontists to manage such medical conditions in a dental office.", [["endodontists", "TREATMENT", 42, 54], ["such medical conditions", "PROBLEM", 65, 88]]], ["It should be noted that this book covers endodontic considerations in commonly occurring medical conditions, a comprehensive list of all medical conditions is exhaustive and beyond the scope of this book.", [["endodontic considerations", "TREATMENT", 41, 66], ["all medical conditions", "PROBLEM", 133, 155]]], ["For information on other medical conditions and more detail on those listed below, the reader is advised to refer to other books and journals and to consult their medical colleagues with respect to specific patient cases.Importance of History TakingObtaining a thorough medical history is of great importance [2].", [["patient", "ORGANISM", 207, 214], ["patient", "SPECIES", 207, 214]]], ["It is an information gathering process for assessing a patient\u2019s health status and comprises a systematic review of the patient\u2019s chief or primary complaint, a detailed history related to the complaint, information about past and present medical conditions, pertinent social and family histories, and a review of symptoms by organ system.", [["organ system", "ANATOMY", 325, 337], ["patient", "ORGANISM", 55, 62], ["patient", "ORGANISM", 120, 127], ["organ", "ORGAN", 325, 330], ["patient", "SPECIES", 55, 62], ["patient", "SPECIES", 120, 127], ["symptoms", "PROBLEM", 313, 321]]], ["Interpretation of this information collected achieves three important objectives: enables the monitoring of medical conditions and the evaluation of underlying systemic conditions of which the patient may or may not be aware, provides a basis for determining whether dental treatment might affect the systemic health of the patient, and provides an initial starting point for assessing the possible influence of the patient\u2019s systemic health on the patient\u2019s oral health and/or dental treatment [3, 4].Importance of History TakingEach identified condition during the process of history taking can affect dental care in a unique manner.", [["oral", "ANATOMY", 459, 463], ["patient", "ORGANISM", 193, 200], ["patient", "ORGANISM", 324, 331], ["patient", "ORGANISM", 416, 423], ["patient", "ORGANISM", 449, 456], ["oral", "ORGANISM_SUBDIVISION", 459, 463], ["patient", "SPECIES", 193, 200], ["patient", "SPECIES", 324, 331], ["patient", "SPECIES", 416, 423], ["patient", "SPECIES", 449, 456], ["medical conditions", "TREATMENT", 108, 126], ["the evaluation", "TEST", 131, 145], ["underlying systemic conditions", "PROBLEM", 149, 179], ["dental treatment", "TREATMENT", 267, 283], ["dental treatment", "TREATMENT", 478, 494]]], ["For example, medication prescribed for a medical condition might produce a problem during the administration of a local anesthetic, or it could interact with pain medication prescribed posttreatment.", [["pain", "DISEASE", 158, 162], ["medication", "TREATMENT", 13, 23], ["a medical condition", "PROBLEM", 39, 58], ["a local anesthetic", "TREATMENT", 112, 130], ["pain medication", "TREATMENT", 158, 173]]], ["Certain medically compromised patients should only be treated in a hospital setting where emergency issues, should they arise, can be immediately addressed and promptly attended to in a controlled manner.Importance of History TakingPast dental history (PDH) should also be obtained as a review of systems, especially when the patient presents with complicating dental and medical factors such as restorative and periodontal needs coupled with a systemic disorder such as diabetes.", [["systemic disorder", "DISEASE", 445, 462], ["diabetes", "DISEASE", 471, 479], ["patients", "ORGANISM", 30, 38], ["patient", "ORGANISM", 326, 333], ["patients", "SPECIES", 30, 38], ["patient", "SPECIES", 326, 333], ["complicating dental and medical factors", "PROBLEM", 348, 387], ["restorative and periodontal needs", "PROBLEM", 396, 429], ["a systemic disorder", "PROBLEM", 443, 462], ["diabetes", "PROBLEM", 471, 479], ["diabetes", "OBSERVATION", 471, 479]]], ["Details of any previous untoward complications of dental treatment must be recorded or must be obtained subsequently if not immediately available from the patient.Importance of History TakingDental treatment causes changes to the patient\u2019s homeostasis.", [["patient", "ORGANISM", 155, 162], ["patient", "ORGANISM", 230, 237], ["patient", "SPECIES", 155, 162], ["patient", "SPECIES", 230, 237], ["dental treatment", "TREATMENT", 50, 66], ["History TakingDental treatment", "TREATMENT", 177, 207]]], ["A risk assessment should be performed to evaluate and determine the modifications to be required before, during, and after dental treatment.", [["A risk assessment", "TEST", 0, 17], ["dental treatment", "TREATMENT", 123, 139]]], ["Different modifications may be necessary at each stage of treatment such as antibiotic prophylaxis or steroid replacement may be necessary before treatment, or it may not be possible to place the patient in a supine position during dental procedures, or specific hemostatic agents may need to be employed after extractions.", [["steroid", "CHEMICAL", 102, 109], ["steroid", "CHEMICAL", 102, 109], ["steroid", "SIMPLE_CHEMICAL", 102, 109], ["patient", "ORGANISM", 196, 203], ["patient", "SPECIES", 196, 203], ["Different modifications", "TREATMENT", 0, 23], ["treatment", "TREATMENT", 58, 67], ["antibiotic prophylaxis", "TREATMENT", 76, 98], ["steroid replacement", "TREATMENT", 102, 121], ["treatment", "TREATMENT", 146, 155], ["dental procedures", "TREATMENT", 232, 249], ["specific hemostatic agents", "TREATMENT", 254, 280], ["extractions", "TREATMENT", 311, 322]]], ["Many different medical conditions are discussed hereby, and protocols for the modification of dental care are suggested.Importance of History TakingIn the patient with pre-existing disease, preparation for dental treatment should include determination of disease status.", [["patient", "ORGANISM", 155, 162], ["patient", "SPECIES", 155, 162], ["dental care", "TREATMENT", 94, 105], ["pre-existing disease", "PROBLEM", 168, 188], ["dental treatment", "TREATMENT", 206, 222], ["disease status", "PROBLEM", 255, 269], ["disease", "OBSERVATION", 181, 188]]], ["The clinician should have an understanding of the nature of the patient\u2019s disease and how it can impact their physiology and his/her response to dental management and postdental treatment healing.", [["patient", "ORGANISM", 64, 71], ["patient", "SPECIES", 64, 71], ["dental management", "TREATMENT", 145, 162], ["postdental treatment healing", "TREATMENT", 167, 195]]], ["Knowing how to manage potential complications is also important and is discussed in the following chapter.White Coat Hypertension ::: Hypertension ::: Cardiac DisordersOffice BP is usually higher than BP measured out of the office, which can be attributed to anxiety and/or a conditional response to the unusual situation [1].", [["Cardiac", "ANATOMY", 151, 158], ["Hypertension", "DISEASE", 117, 129], ["Hypertension", "DISEASE", 134, 146], ["anxiety", "DISEASE", 259, 266], ["BP", "PROTEIN", 201, 203], ["potential complications", "PROBLEM", 22, 45], ["White Coat Hypertension", "PROBLEM", 106, 129], ["Hypertension", "PROBLEM", 134, 146], ["Cardiac DisordersOffice BP", "TEST", 151, 177], ["BP", "TEST", 201, 203], ["anxiety", "PROBLEM", 259, 266], ["Hypertension", "OBSERVATION", 117, 129]]], ["White coat hypertension (WCH) refers to a persistently elevated office blood pressure in the presence of a normal blood pressure outside of the office [4].", [["blood", "ANATOMY", 71, 76], ["blood", "ANATOMY", 114, 119], ["hypertension", "DISEASE", 11, 23], ["WCH", "DISEASE", 25, 28], ["blood", "ORGANISM_SUBSTANCE", 71, 76], ["blood", "ORGANISM_SUBSTANCE", 114, 119], ["White coat hypertension", "PROBLEM", 0, 23], ["a persistently elevated office blood pressure", "PROBLEM", 40, 85], ["hypertension", "OBSERVATION", 11, 23], ["normal", "OBSERVATION", 107, 113]]], ["WCH is different from the white coat effect (WCE), which refers to a high office blood pressure but whereby hypertension may or may not be present outside the office setting.", [["blood", "ANATOMY", 81, 86], ["WCH", "DISEASE", 0, 3], ["hypertension", "DISEASE", 108, 120], ["WCH", "SIMPLE_CHEMICAL", 0, 3], ["blood", "ORGANISM_SUBSTANCE", 81, 86], ["WCH", "PROBLEM", 0, 3], ["hypertension", "PROBLEM", 108, 120], ["different", "OBSERVATION_MODIFIER", 7, 16], ["white coat", "OBSERVATION_MODIFIER", 26, 36], ["effect", "OBSERVATION_MODIFIER", 37, 43], ["hypertension", "OBSERVATION", 108, 120], ["may not be", "UNCERTAINTY", 128, 138]]], ["Masked hypertension refers to when a patient has a normal office blood pressure but has hypertension outside of the office (Table 12.2).", [["blood", "ANATOMY", 65, 70], ["hypertension", "DISEASE", 7, 19], ["hypertension", "DISEASE", 88, 100], ["patient", "ORGANISM", 37, 44], ["blood", "ORGANISM_SUBSTANCE", 65, 70], ["patient", "SPECIES", 37, 44], ["Masked hypertension", "PROBLEM", 0, 19], ["hypertension", "PROBLEM", 88, 100], ["hypertension", "OBSERVATION", 7, 19], ["normal", "OBSERVATION", 51, 57], ["hypertension", "OBSERVATION", 88, 100]]]], "f3eca202febb9a227ae68405dca3a108356b8cd3": [["IntroductionThe rapid and global spread of COVID-19 led the World Health Organization (WHO) to declare it a pandemic on March 11, 2020.", [["COVID", "TEST", 43, 48], ["rapid", "OBSERVATION_MODIFIER", 16, 21], ["global", "OBSERVATION_MODIFIER", 26, 32], ["spread", "OBSERVATION_MODIFIER", 33, 39]]], ["One major factor that contributes to the spread of the virus is the apparently large number of undiagnosed infected individuals.", [["the virus", "PROBLEM", 51, 60], ["undiagnosed infected individuals", "PROBLEM", 95, 127], ["spread", "OBSERVATION_MODIFIER", 41, 47], ["virus", "OBSERVATION", 55, 60], ["large", "OBSERVATION_MODIFIER", 79, 84], ["number", "OBSERVATION_MODIFIER", 85, 91], ["undiagnosed", "OBSERVATION_MODIFIER", 95, 106], ["infected", "OBSERVATION", 107, 115]]], ["This knowledge gap facilitates the silent propagation of the virus, delays the response of public health officials and results in an explosion in the number of cases 1,2 .IntroductionOne reason for this knowledge gap is insufficient testing.", [["the virus", "PROBLEM", 57, 66]]], ["While the current gold standard for COVID-19 diagnosis is detection of viral RNA in a reverse transcription PCR test, the number of tests is limited by financial and logistic constraints.", [["viral RNA", "RNA", 71, 80], ["viral RNA", "PROBLEM", 71, 80], ["a reverse transcription PCR test", "TEST", 84, 116], ["tests", "TEST", 132, 137], ["viral RNA", "OBSERVATION", 71, 80]]], ["This creates the need for a prioritization mechanism to allocate tests and resources more efficiently towards individuals who are more likely to test positive, leading to earlier identification of COVID-19 patients and reduced spread of the virus.", [["individuals", "ORGANISM", 110, 121], ["patients", "ORGANISM", 206, 214], ["patients", "SPECIES", 206, 214], ["tests", "TEST", 65, 70], ["COVID", "TEST", 197, 202], ["reduced spread of the virus", "PROBLEM", 219, 246]]], ["Despite this need, most countries still employ a simplistic testing strategy based on display of symptoms associated with the disease and either close epidemiological contact with a confirmed COVID-19 case or belonging to a high risk group 3 .", [["a simplistic testing strategy", "TEST", 47, 76], ["symptoms", "PROBLEM", 97, 105], ["the disease", "PROBLEM", 122, 133]]], ["In practice, these strategies lead to a relatively small fraction of positive tests among those tested and thus to inefficient use of the precious testing resources.IntroductionHere, we present a model that provides statistically significant estimates of the probability of an individual to test positive for SARS-CoV-2 infection in a PCR test, based on a national symptom survey that we distributed in Israel.", [["SARS-CoV-2 infection", "DISEASE", 309, 329], ["SARS-CoV-2", "ORGANISM", 309, 319], ["SARS-CoV-2", "SPECIES", 309, 319], ["a relatively small fraction of positive tests", "PROBLEM", 38, 83], ["the precious testing resources", "TREATMENT", 134, 164], ["SARS", "PROBLEM", 309, 313], ["CoV", "PROBLEM", 314, 317], ["2 infection", "PROBLEM", 318, 329], ["a PCR test", "TEST", 333, 343], ["a national symptom survey", "TEST", 354, 379]]], ["Notably, while most studies describing the clinical characteristics of COVID-19 cases were based on symptoms of hospitalized patients 4 , our survey data allowed us to also study symptoms of milder cases and reveal which symptoms hold the highest predictive power for COVID-19 diagnosis.", [["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 125, 133], ["COVID", "TEST", 71, 76], ["symptoms", "PROBLEM", 100, 108], ["our survey data", "TEST", 138, 153], ["symptoms of milder cases", "PROBLEM", 179, 203], ["which symptoms", "PROBLEM", 215, 229], ["COVID", "TEST", 268, 273]]], ["Using our model, the risk for a positive COVID-19 test can be evaluated in less than a minute and without added costs, or risk of exposure to a suspected patient.", [["patient", "ORGANISM", 154, 161], ["patient", "SPECIES", 154, 161], ["a positive COVID", "TEST", 30, 46]]], ["Our approach can thus be used globally to make more efficient use of available testing capacities, by significantly increasing the fraction of positive tests obtained, and by rapidly identifying individuals that should be isolated until definitive test results are obtained.Introduction.", [["available testing capacities", "TEST", 69, 97], ["positive tests", "TEST", 143, 157], ["definitive test results", "TEST", 237, 260]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)IntroductionThe copyright holder for this preprint this version posted May 21, 2020. . https://doi.org/10.1101/2020.05.18.20105569 doi: medRxiv preprintDataIn this study, we utilized data that originates from two versions of a one-minute survey that was developed and deployed by our research group in the early stages of the COVID-19 spread in Israel 5 .", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 214, 234], ["this study", "TEST", 361, 371], ["the COVID", "TEST", 524, 533], ["med", "ANATOMY", 105, 108]]], ["The online version of the survey includes questions relating to age, gender, prior medical conditions, smoking habits, self-reported symptoms and geographical location (see section 1a in the supplementary appendix).", [["appendix", "ORGAN", 205, 213], ["prior medical conditions", "PROBLEM", 77, 101], ["self-reported symptoms", "PROBLEM", 119, 141], ["appendix", "ANATOMY", 205, 213]]], ["Questions regarding prior medical conditions and symptoms included in the survey were carefully chosen by medical professionals.", [["prior medical conditions", "PROBLEM", 20, 44], ["symptoms", "PROBLEM", 49, 57]]], ["Each participant is asked to fill the survey once a day for himself and for family members that are unable to fill it for themselves (e.g. children and the elderly).", [["children", "ORGANISM", 139, 147], ["participant", "SPECIES", 5, 16], ["children", "SPECIES", 139, 147]]], ["The survey is anonymous to maintain the privacy of the participants, and has been collected since March 14th, 2020.", [["participants", "SPECIES", 55, 67]]], ["As the number of COVID-19 diagnosed individuals in Israel rose, in some cities more than others, a shortened version of the survey was deployed using an Interactive Voice Response (IVR) platform.", [["COVID", "TEST", 17, 22]]], ["This version of the survey included information on respondents' age group, gender, presence of prior medical conditions, general feeling and a partial list of symptoms, including fever, cough, shortness of breath, sore throat and loss of taste or smell (see Section 1b in the supplementary appendix).", [["fever", "DISEASE", 179, 184], ["cough", "DISEASE", 186, 191], ["shortness of breath", "DISEASE", 193, 212], ["sore throat", "DISEASE", 214, 225], ["loss of taste or smell", "DISEASE", 230, 252], ["appendix", "ORGAN", 290, 298], ["prior medical conditions", "PROBLEM", 95, 119], ["general feeling", "PROBLEM", 121, 136], ["symptoms", "PROBLEM", 159, 167], ["fever", "PROBLEM", 179, 184], ["cough", "PROBLEM", 186, 191], ["shortness of breath", "PROBLEM", 193, 212], ["sore throat", "PROBLEM", 214, 225], ["loss of taste or smell", "PROBLEM", 230, 252], ["sore throat", "ANATOMY", 214, 225], ["appendix", "ANATOMY", 290, 298]]], ["Cities were targeted to participate in the IVR version of the survey according to the number of diagnosed patients and an increased concern for COVID-19 outbreaks (Table S1) .", [["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114], ["COVID", "TEST", 144, 149]]], ["Starting April 5, 2020, citizens in the targeted cities were contacted and responses were collected anonymously.", [["citizens", "TREATMENT", 24, 32]]], ["This study followed the Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD) reporting guideline 6 .Study Design and PopulationOverall, 695,586 and 66,447 responses were collected up until April 26th, 2020, from the online and IVR versions of the survey, respectively.", [["This study", "TEST", 0, 10], ["Study Design and PopulationOverall", "TEST", 152, 186]]], ["Since children express different clinical manifestations of COVID-19 infection 7,8 , we decided to focus our analysis only on adults (age above 20 years old).", [["COVID", "DISEASE", 60, 65], ["infection", "DISEASE", 69, 78], ["children", "ORGANISM", 6, 14], ["adults", "ORGANISM", 126, 132], ["children", "SPECIES", 6, 14], ["COVID-19 infection", "PROBLEM", 60, 78], ["our analysis", "TEST", 105, 117]]], ["To avoid translation discrepancies, we included only responses in Hebrew.", [["translation discrepancies", "PROBLEM", 9, 34]]], ["We also excluded responses that did not meet quality control criteria, such as a reasonable age (<120 years old) and body temperature (35-43\u2103) or responses suspected as spam (see Section 3 in the supplementary appendix) (Figure 1 ).", [["body", "ANATOMY", 117, 121], ["body", "ORGANISM_SUBDIVISION", 117, 121], ["body temperature", "TEST", 117, 133], ["appendix", "ANATOMY", 210, 218]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Study Design and PopulationThe copyright holder for this preprint this version posted May 21, 2020. . https://doi.org/10.1101/2020.05.18.20105569 doi: medRxiv preprint eventually included from the IVR version of the survey.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["Study Design", "TEST", 202, 214], ["The copyright holder", "TREATMENT", 229, 249], ["medRxiv preprint", "TREATMENT", 353, 369], ["med", "ANATOMY", 105, 108]]], ["Since surveyed cities were at relatively high risk (Table S1 ), the prevalence of COVID-19 diagnosed responders in the IVR data was 1.14%, 6 times higher than the national prevalence of 0.18% 3 .", [["COVID", "TEST", 82, 87], ["the IVR data", "TEST", 115, 127]]], ["These cities also had very high response rates, between 6% to 16% of the cities' population (Table S1 ).", [["very high response rates", "PROBLEM", 22, 46], ["very", "OBSERVATION_MODIFIER", 22, 26], ["high response", "OBSERVATION", 27, 40]]], ["From the online version of the survey, we randomly sampled a single response for each individual that was recognized by a unique identifier we created (see Section 4 in the supplementary appendix), and when an individual reported a COVID-19 diagnosis, we randomly sampled one response only from those which included a positive diagnosis answer.", [["appendix", "ORGAN", 187, 195], ["appendix", "ANATOMY", 187, 195]]], ["A total of 131,166 responses were identified in the online version, of which 0.09% reported a positive COVID-19 diagnosis, which is closer to the national prevalence of 0.18% 3 .Study Design and PopulationThe characteristics of these unique responders are described in Table S2 of the supplementary appendix.Study Design and PopulationFor the integration of the two survey versions, all 33,737 IVR responses were combined together with all 114 uniquely identified responders in the online survey that self-reported COVID-19 diagnosis and a random sample of 9,901 undiagnosed responders in the online version, to maintain the same diagnosis prevalence as in the IVR version ( Figure 1 ).", [["appendix", "ORGAN", 299, 307], ["Study Design", "TEST", 178, 190], ["Study Design", "TEST", 308, 320], ["a random sample", "TEST", 538, 553], ["supplementary appendix", "ANATOMY", 285, 307]]], ["Overall, 43,752 responses were eventually included in the study, of which 498 self-reported as being COVID-19 diagnosed.", [["the study", "TEST", 54, 63], ["COVID", "TEST", 101, 106]]], ["The characteristics of these responders are described in Table 1 .Predicting the Outcome of a COVID-19 TestWe defined survey self-reporting of a COVID-19 laboratory confirmed diagnosis as our outcome.", [["a COVID", "TEST", 92, 99], ["a COVID", "TEST", 143, 150]]], ["The second model, which we term the extended features model, was constructed using only responses from the online version, and included additional symptoms and questions that were not part of the IVR survey.", [["additional symptoms", "PROBLEM", 136, 155]]], ["We trained both the primary and extended features models using LogisticPredicting the Outcome of a COVID-19 TestRegression.", [["a COVID-19 TestRegression", "TREATMENT", 97, 122]]], ["In addition, in order to capture nonlinear interactions and interactions amongst features, in both cases we also constructed models using a Gradient Boosting Decision Trees algorithm 9 .", [["a Gradient Boosting", "TREATMENT", 138, 157]]], ["To test the validity of our models, all model constructions were done using the framework of cross-validation, in which model performance is evaluated on a subset of the data that was not used in the model's construction.", [["cross-validation", "TEST", 93, 109]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 21, 2020. . https://doi.org/10.1101/2020.05.18.20105569 doi: medRxiv preprint information on handling of missing values and the models construction process, see Section 6 in the supplementary appendix.Primary ModelThe primary model was constructed using responses to both the IVR and the online version of the survey.Primary ModelFeatures included in this model were determined by the IVR version, since it included a subset of the online version questions.", [["CC", "CHEMICAL", 0, 2], ["appendix", "ORGAN", 456, 464], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["missing values", "PROBLEM", 369, 383], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["appendix", "ANATOMY", 456, 464]]], ["These consisted of age group, gender, presence of prior medical conditions, general feeling, and the following symptoms: fever, cough, shortness of breath, sore throat and loss of taste or smell.Extended Features ModelThe extended features model was constructed using only responses from the online version of the survey, as it had 14 additional features that were not available in the IVR version.", [["fever", "DISEASE", 121, 126], ["cough", "DISEASE", 128, 133], ["shortness of breath", "DISEASE", 135, 154], ["sore throat", "DISEASE", 156, 167], ["loss of taste or smell", "DISEASE", 172, 194], ["prior medical conditions", "PROBLEM", 50, 74], ["general feeling", "PROBLEM", 76, 91], ["the following symptoms", "PROBLEM", 97, 119], ["fever", "PROBLEM", 121, 126], ["cough", "PROBLEM", 128, 133], ["shortness of breath", "PROBLEM", 135, 154], ["sore throat", "PROBLEM", 156, 167], ["loss of taste or smell", "PROBLEM", 172, 194], ["the survey", "TEST", 310, 320]]], ["This extended list added dry cough and moist cough (instead of general cough in the primary model), fatigue, muscle pain, rhinorrhea, diarrhea, nausea or vomiting, chills, confusion and reporting on presence of specific prior medical conditions separately (as opposed to the presence of any of the prior medical conditions in the primary model).Baseline ModelsTo assess the contribution of reported symptoms and prior medical conditions to both the primary model and the extended features model (in both the Logistic Regression and the Gradient Boosting Decision Trees versions), we constructed baseline models using only age group and gender information to predict our outcome.Analysis of feature contributionsTo gain insight into the features that contribute most to the predicted probability of being diagnosed with COVID-19 of our models, we analyzed feature contribution in the Gradient Boosting Decision Trees models using SHAP (SHapley Additive exPlanation) 10 .", [["muscle", "ANATOMY", 109, 115], ["cough", "DISEASE", 29, 34], ["cough", "DISEASE", 45, 50], ["cough", "DISEASE", 71, 76], ["fatigue", "DISEASE", 100, 107], ["muscle pain", "DISEASE", 109, 120], ["rhinorrhea", "DISEASE", 122, 132], ["diarrhea", "DISEASE", 134, 142], ["nausea", "DISEASE", 144, 150], ["vomiting", "DISEASE", 154, 162], ["chills", "DISEASE", 164, 170], ["confusion", "DISEASE", 172, 181], ["muscle", "ORGAN", 109, 115], ["dry cough", "PROBLEM", 25, 34], ["moist cough", "PROBLEM", 39, 50], ["general cough", "PROBLEM", 63, 76], ["fatigue", "PROBLEM", 100, 107], ["muscle pain", "PROBLEM", 109, 120], ["rhinorrhea", "PROBLEM", 122, 132], ["diarrhea", "PROBLEM", 134, 142], ["nausea", "PROBLEM", 144, 150], ["vomiting", "PROBLEM", 154, 162], ["chills", "PROBLEM", 164, 170], ["confusion", "PROBLEM", 172, 181], ["reported symptoms", "PROBLEM", 390, 407], ["prior medical conditions", "PROBLEM", 412, 436], ["COVID", "TEST", 819, 824], ["SHAP (SHapley Additive exPlanation)", "TREATMENT", 929, 964], ["muscle", "ANATOMY", 109, 115], ["rhinorrhea", "OBSERVATION", 122, 132]]], ["SHAP aims to interpret the output of a machine learning model by estimating the Shapley value of each feature, which represents the average change in the output of the model, by conditioning on that feature while introducing other features one at a time, over all possible features ordering.Analysis of feature contributions.", [["average", "OBSERVATION_MODIFIER", 132, 139], ["change", "OBSERVATION_MODIFIER", 140, 146], ["output", "OBSERVATION_MODIFIER", 154, 160]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 21, 2020. . https://doi.org/10.1101/2020.05.18.20105569 doi: medRxiv preprint and to identify which features dominated in each prediction.(which was not certified by peer review)We further analyzed SHAP interaction values, which uses the 'Shapely interaction index' to capture local interaction effects between features 10 .", [["CC", "CHEMICAL", 0, 2], ["SHAP", "GENE_OR_GENE_PRODUCT", 462, 466], ["SHAP", "PROTEIN", 462, 466], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Interaction values are calculated for each pair of the model's features, and for each individual prediction of the model, allowing us to uncover interaction patterns between pairs of features.(which was not certified by peer review)We placed particular emphasis on the contribution of participants' age and the interaction of age with all other features.(which was not certified by peer review).", [["participants", "SPECIES", 285, 297], ["Interaction values", "TEST", 0, 18]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 21, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["In a perfectly calibrated model, the distribution of the predicted probabilities is equal to the distribution of outcomes observed in the training data.", [["the training data", "TEST", 134, 151], ["distribution", "OBSERVATION_MODIFIER", 37, 49]]], ["The model has a positive predictive value (PPV) of 46.3%, at 10% sensitivity, while the baseline model only has 0.014%, at 10% sensitivity.(which was not certified by peer review)As an additional validation for the risk scores obtained, we compared the model predictions on the online survey .", [["PPV", "TEST", 43, 46], ["an additional validation", "TEST", 182, 206], ["the risk scores", "TEST", 211, 226], ["positive", "OBSERVATION_MODIFIER", 16, 24]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. features the algorithm found to be most contributing ( Figure 4B ).(which was not certified by peer review)As age was reported as a dominant factor in COVID-19 infection and its clinical manifestation 11 , we examined the interaction of age with every symptom using SHAP interaction values (see Methods).", [["CC", "CHEMICAL", 0, 2], ["infection", "DISEASE", 322, 331], ["COVID-19", "CELL", 313, 321], ["COVID-19", "SPECIES", 313, 321], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["the algorithm", "TEST", 171, 184], ["a dominant factor in COVID-19 infection", "PROBLEM", 292, 331], ["every symptom", "PROBLEM", 408, 421], ["SHAP interaction values", "PROBLEM", 428, 451], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["dominant", "OBSERVATION_MODIFIER", 294, 302], ["infection", "OBSERVATION", 322, 331]]], ["The contribution of age to the probability of being diagnosed with COVID-19 is the highest in the oldest age group (>70 years old) ( Figure 5B ).", [["COVID", "TEST", 67, 72]]], ["Presence of cough and loss of taste or smell exhibits a sharp transition-type (sigmoid-like) interaction with age, such that above the age of 40 years old, presence of each of these symptoms sharply increases the model's predicted probability of COVID-19 infection ( Figure 5G-H) .", [["cough", "DISEASE", 12, 17], ["loss of taste or smell", "DISEASE", 22, 44], ["infection", "DISEASE", 255, 264], ["COVID-19", "SPECIES", 246, 254], ["cough", "PROBLEM", 12, 17], ["loss of taste", "PROBLEM", 22, 35], ["smell", "PROBLEM", 39, 44], ["a sharp transition", "PROBLEM", 54, 72], ["these symptoms", "PROBLEM", 176, 190], ["COVID-19 infection", "PROBLEM", 246, 264], ["cough", "OBSERVATION", 12, 17], ["sharp", "OBSERVATION_MODIFIER", 56, 61], ["transition", "OBSERVATION_MODIFIER", 62, 72], ["sigmoid", "ANATOMY", 79, 86]]], ["In contrast, shortness of breath and sore throat show a more gradual (parabolic-like) interaction with age with presence of these symptoms increasing the model's prediction more gradually as the age of the subject being predicted increases ( Figure 5I -J).", [["shortness of breath", "DISEASE", 13, 32], ["sore throat", "DISEASE", 37, 48], ["throat", "ORGANISM_SUBDIVISION", 42, 48], ["shortness of breath", "PROBLEM", 13, 32], ["sore throat", "PROBLEM", 37, 48], ["a more gradual (parabolic-like) interaction", "PROBLEM", 54, 97], ["these symptoms", "PROBLEM", 124, 138]]], ["Negative answers to all these features show no interaction with age.", [["no", "UNCERTAINTY", 44, 46]]], ["Other examined features, such as fever and general feeling, do not show such interactions with age.(which was not certified by peer review).", [["fever", "DISEASE", 33, 38], ["fever", "PROBLEM", 33, 38], ["general feeling", "PROBLEM", 43, 58]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 21, 2020. . https://doi.org/10.1101/2020.05.18.20105569 doi: medRxiv preprintDiscussionIn this study we constructed a model that predicts the probability of individuals to test positive for COVID-19.DiscussionOur model is based on 9 simple questions that every person can easily answer in less than a minute from the comfort of their home.", [["CC", "CHEMICAL", 0, 2], ["person", "SPECIES", 525, 531], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["this study", "TEST", 354, 364], ["COVID", "TEST", 454, 459], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Our model can assist the worldwide fight against COVID-19 by better prioritizing the limited tests available without additional costs or risk of exposure to suspected patients, thereby increasing the rate at which positive individuals can be identified and isolated.DiscussionIn Israel, as well as in many other countries, due to limited testing resources, suspected patients are only tested if they were exposed to a COVID-19 confirmed patient as well as exhibited acute respiratory symptoms 3 .", [["respiratory", "ANATOMY", 472, 483], ["patients", "ORGANISM", 167, 175], ["patients", "ORGANISM", 367, 375], ["patient", "ORGANISM", 437, 444], ["patients", "SPECIES", 167, 175], ["patients", "SPECIES", 367, 375], ["patient", "SPECIES", 437, 444], ["COVID", "TEST", 49, 54], ["the limited tests", "TEST", 81, 98], ["positive individuals", "PROBLEM", 214, 234], ["a COVID", "TEST", 416, 423], ["acute respiratory symptoms", "PROBLEM", 466, 492], ["acute", "OBSERVATION_MODIFIER", 466, 471], ["respiratory symptoms", "OBSERVATION", 472, 492]]], ["By taking an unbiased approach to predicting COVID-19 diagnosis from symptoms data, our analysis highlights the importance of additional symptoms.", [["COVID-19", "DNA", 45, 53], ["symptoms data", "PROBLEM", 69, 82], ["our analysis", "TEST", 84, 96], ["additional symptoms", "PROBLEM", 126, 145]]], ["Of note, anosmia and ageusia that were less described in patients in the early stages of the COVID-19 pandemic 4,12 were the most impactful features in both models for predicting COVID-19 diagnosis as well as in an odds-ratio analysis.", [["anosmia", "DISEASE", 9, 16], ["patients", "ORGANISM", 57, 65], ["COVID-19", "DNA", 179, 187], ["patients", "SPECIES", 57, 65], ["anosmia", "PROBLEM", 9, 16], ["ageusia", "PROBLEM", 21, 28], ["the COVID", "TEST", 89, 98], ["predicting COVID", "TEST", 168, 184], ["an odds-ratio analysis", "TEST", 212, 234], ["less", "OBSERVATION_MODIFIER", 39, 43]]], ["This is in line with recent literature demonstrating the importance of these symptoms in early detection and identification of the disease 13, 14, 15 .", [["these symptoms", "PROBLEM", 71, 85], ["early detection", "TEST", 89, 104], ["the disease", "PROBLEM", 127, 138]]], ["Our model also successfully recapitulated patterns of the disease that are described in the literature, such as its complex relationship with age 11 .", [["the disease", "PROBLEM", 54, 65], ["successfully", "OBSERVATION_MODIFIER", 15, 27], ["recapitulated", "OBSERVATION_MODIFIER", 28, 41], ["patterns", "OBSERVATION_MODIFIER", 42, 50], ["disease", "OBSERVATION", 58, 65]]], ["In addition, our model unraveled several patterns that are not described in the literature, such as the different patterns of interactions that particular symptoms have with age, suggesting variation of the clinical manifestation in different age groups.", [["particular symptoms", "PROBLEM", 144, 163], ["the clinical manifestation", "PROBLEM", 203, 229], ["several", "OBSERVATION_MODIFIER", 33, 40]]], ["Although our analysis is purely predictive and not causal, these new patterns may be used to devise better testing policies, and pave the way for future studies that can uncover new aspects of the disease that were not studied to date.DiscussionAnalysis of an extended features model that included 23 features compared to 9 in the primary model, validated our choice of questions in the shortened version of the survey and suggested that fatigue should also be considered.", [["fatigue", "DISEASE", 438, 445], ["our analysis", "TEST", 9, 21], ["future studies", "TEST", 146, 160], ["the disease", "PROBLEM", 193, 204], ["fatigue", "PROBLEM", 438, 445], ["disease", "OBSERVATION", 197, 204]]], ["In addition, the extended features model suggested that while dry cough has an essential role in predicting COVID-19 diagnosis, moist cough does not and thus may help distinguish between cases of COVID-19 and other infections.", [["dry cough", "DISEASE", 62, 71], ["cough", "DISEASE", 134, 139], ["infections", "DISEASE", 215, 225], ["dry cough", "PROBLEM", 62, 71], ["moist cough", "PROBLEM", 128, 139], ["COVID", "TEST", 196, 201], ["other infections", "PROBLEM", 209, 225], ["infections", "OBSERVATION", 215, 225]]], ["Some of the most contributing symptoms to the prediction of a COVID-19 diagnosis are .", [["the most contributing symptoms", "PROBLEM", 8, 38], ["a COVID", "TEST", 60, 67]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 21, 2020. . https://doi.org/10.1101/2020.05.18.20105569 doi: medRxiv preprint currently not included in the Israeli testing policy 3 , such as loss of taste or smell and sore throat.", [["CC", "CHEMICAL", 0, 2], ["loss of taste or smell", "DISEASE", 407, 429], ["sore throat", "DISEASE", 434, 445], ["throat", "ORGANISM_SUBDIVISION", 439, 445], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv", "TREATMENT", 325, 332], ["loss of taste", "PROBLEM", 407, 420], ["smell", "PROBLEM", 424, 429], ["sore throat", "PROBLEM", 434, 445], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["sore throat", "ANATOMY", 434, 445]]], ["Our analysis suggests that adding these symptoms to the testing policy may help discriminate which individuals should be tested, and improve testing prioritization.(which was not certified by peer review)While informative, our feature contribution analysis has several limitations.", [["individuals", "ORGANISM", 99, 110], ["Our analysis", "TEST", 0, 12], ["these symptoms", "PROBLEM", 34, 48]]], ["First, we did not include children in our datasets and thus, symptoms such as nausea or vomiting and diarrhea that were mostly described in children 7, 8 , may have a more significant part in models designed for younger age groups.", [["nausea", "DISEASE", 78, 84], ["vomiting", "DISEASE", 88, 96], ["diarrhea", "DISEASE", 101, 109], ["children", "ORGANISM", 26, 34], ["children", "SPECIES", 26, 34], ["children", "SPECIES", 140, 148], ["symptoms", "PROBLEM", 61, 69], ["nausea", "PROBLEM", 78, 84], ["vomiting", "PROBLEM", 88, 96], ["diarrhea", "PROBLEM", 101, 109]]], ["Second, although we included a large set of prior medical conditions that may have a role in COVID-19 susceptibility, some of these conditions are not highly prevalent in our dataset and their contribution may thus be underestimated in our model.", [["prior medical conditions", "PROBLEM", 44, 68], ["COVID", "TEST", 93, 98], ["large", "OBSERVATION_MODIFIER", 31, 36]]], ["Finally, body temperature was the only non-mandatory question in our survey, and may thus have higher predictive power than portrayed within our model.(which was not certified by peer review)Several studies attempted to simulate and predict different aspects of COVID-19, such as hospital admissions, diagnosis, prognosis and mortality risk, using mostly age, body temperature, medical tests and symptoms 16 .(which was not certified by peer review)Most diagnostic models published to date were based on datasets from China and included complex features that had to be extracted through blood tests and imaging scans 16 .", [["body", "ANATOMY", 9, 13], ["body", "ANATOMY", 360, 364], ["blood", "ANATOMY", 587, 592], ["body", "ORGANISM_SUBDIVISION", 9, 13], ["body", "ORGANISM_SUBDIVISION", 360, 364], ["blood", "ORGANISM_SUBSTANCE", 587, 592], ["body temperature", "TEST", 9, 25], ["Several studies", "TEST", 191, 206], ["COVID", "TEST", 262, 267], ["medical tests", "TEST", 378, 391], ["symptoms", "PROBLEM", 396, 404], ["blood tests", "TEST", 587, 598], ["imaging scans", "TEST", 603, 616]]], ["In this work, we devised a prediction model which was based solely on self-reported information, and as such it could be easily deployed and used instantly in other countries.(which was not certified by peer review)Our study has several additional limitations.", [["a prediction model", "TEST", 25, 43], ["Our study", "TEST", 215, 224]]], ["First, our data is biased by Israel's MOH ever changing testing policy, such that at some point all of the COVID-19 positively diagnosed participants in our study had to be eligible for a test under that policy.", [["participants", "SPECIES", 137, 149], ["our study", "TEST", 153, 162], ["a test", "TEST", 186, 192]]], ["An ideal dataset for purposes of devising a classifier should include a large random sampling of the population, but such data coupled with symptom surveys is currently unavailable at large-scale.", [["such data", "TEST", 117, 126], ["symptom surveys", "TEST", 140, 155], ["large", "OBSERVATION_MODIFIER", 72, 77]]], ["Accordingly, all the diagnosed responders in our study are not in the first stage of showing symptoms, but are in some time-lag after diagnosis.", [["our study", "TEST", 45, 54], ["symptoms", "PROBLEM", 93, 101]]], ["In addition, our study is based on self reports of willing participants and is therefore bound to suffer from some selection bias.", [["participants", "SPECIES", 59, 71], ["our study", "TEST", 13, 22]]], ["The bias is significantly reduced in the data collected via the IVR platform, since all residents in the IVR-surveyed cities were actively contacted only .", [["bias", "OBSERVATION", 4, 8], ["significantly", "OBSERVATION_MODIFIER", 12, 25], ["reduced", "OBSERVATION_MODIFIER", 26, 33]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 21, 2020. . https://doi.org/10.1101/2020.05.18.20105569 doi: medRxiv preprint once, on the same day and in the same manner.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["In the online version of the survey we made attempts to reduce this bias by promoting it in several media outlets and by engaging leaders of underrepresented communities.(which was not certified by peer review)Finally, we acknowledge that the ideal choice of a baseline model would be the Israeli MOH testing policy, but since it constantly changed during the pandemic and included questions that were not part of our survey we were unable to compare to it.", [["this bias", "TREATMENT", 63, 72]]], ["Nevertheless, at an unknown sensitivity (as we do not know the actual number of cases), the overall predictive value (PPV) of all tests in Israel was 4.6% 3 , and although the measures are not directly comparable, we believe that our model substantially outperforms this PPV.(which was not certified by peer review)In conclusion, our constructed model predicts COVID-19 PCR test results with high discrimination (positive predictive value (PPV) of 46.3% at a 10% sensitivity) and calibration.", [["COVID", "DNA", 361, 366], ["all tests", "TEST", 126, 135], ["this PPV", "TREATMENT", 266, 274], ["COVID", "TEST", 361, 366], ["PCR test", "TEST", 370, 378], ["high discrimination", "PROBLEM", 392, 411], ["PPV", "TEST", 440, 443]]], ["It also suggests that several symptoms that are currently not included in the Israeli testing policy exhibit intriguing interactions with age and should probably be integrated into revised testing policies.", [["several symptoms", "PROBLEM", 22, 38], ["several", "OBSERVATION_MODIFIER", 22, 29], ["symptoms", "OBSERVATION", 30, 38]]], ["Overall, our approach can be utilized worldwide to direct the limited resources towards individuals who are more likely to test positive for COVID-19, leading to faster isolation of infected patients and therefore to reduced rates of virus spread.(which was not certified by peer review).", [["individuals", "ORGANISM", 88, 99], ["patients", "ORGANISM", 191, 199], ["patients", "SPECIES", 191, 199], ["COVID", "TEST", 141, 146], ["virus spread", "PROBLEM", 234, 246], ["infected", "OBSERVATION", 182, 190], ["virus spread", "OBSERVATION", 234, 246]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 21, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 21, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 21, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 21, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 21, 2020. . https://doi.org/10.1101/2020.05.18.20105569 doi: medRxiv preprint .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv preprint", "TREATMENT", 325, 341], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted May 21, 2020. . https://doi.org/10.1101/2020.05.18.20105569 doi: medRxiv preprint .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 242, 262], ["medRxiv preprint", "TREATMENT", 366, 382], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted May 21, 2020. . https://doi.org/10.1101/2020.05.18.20105569 doi: medRxiv preprintData availability statementModels and tables of de-identified, aggregated data are available at https://github.com/hrossman/Covid19-Survey.Code availability statementSource code for the survey is available at https://github.com/hasadna/avid-covider as an open source project, and can be readily adapted to use in other countries.Ethics DeclarationsThe study protocol was approved by the Weizmann Institute of Science review board (IRB).", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 242, 262], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Informed consent was waived by the IRB, as all identifying details of the participants were removed before the computational analysis.", [["participants", "ORGANISM", 74, 86], ["participants", "SPECIES", 74, 86], ["the computational analysis", "TEST", 107, 133]]], ["Participants were made fully aware of the way in which the data will be stored, handled and shared, which was provided to them and is in accord with the privacy and data-protection policy of the Weizmann Institute of Science (https://weizmann.ac.il/pages/privacy-policy).", [["Participants", "SPECIES", 0, 12]]]], "PMC7510782": [["These aims will be achieved through the following objectives: Review current literature about the adoption of agile, particularly in mobile app development.Investigate the awareness, current usage, and perception of agile by Saudi mobile app practitioners through empirical research.Obtain a deeper insight into the factors that may influence agile adoption in Saudi Arabian mobile app development through empirical research.Design and develop tools and techniques that can support agile adoption in Saudi Arabia\u2019s mobile app industry.", [["empirical research", "TREATMENT", 264, 282]]]], "d97b0f8fe5164d14f7540a510f5684f83f3274e4": [["equipped their wards with wireless pulse oximeters to cope with that surge.", [["wireless pulse oximeters", "TREATMENT", 26, 50]]]], "84424a2facffa0195164a03f361befa4c6fce9f6": [["In this region (including the Caribbean), up to June 14, 2020, 1,581,301 cases have been reported, more than 1,360,000 of them in South America, and 828,810 just in Brazil [5, 6] .", [["region", "ANATOMY_MODIFIER", 8, 14]]], ["This, the largest country in the region, have reported 41,828 deaths (5.05%).", [["deaths", "DISEASE", 62, 68], ["largest", "OBSERVATION_MODIFIER", 10, 17], ["region", "ANATOMY_MODIFIER", 33, 39]]], ["Mexico, the second largest country, has a higher proportion of deaths, 16,488 out of 139,196 (11.85%).", [["deaths", "DISEASE", 63, 69]]], ["On the other side, Chile, although have reported 167,355 cases, only 3,101 deaths have registered (1.85%) [5, 6] .", [["deaths", "DISEASE", 75, 81]]], ["In the region, there have been clear differences in the responses to the disease, with countries such as Colombia, Peru, Bolivia, Chile, Argentina, among others following wide recommendations of quarantine, physical distance and biosecurity education in an early stage of the pandemic, whilst in others such as Brazil or Mexico, this has been delayed, with very well-known consequences.", [["the disease", "PROBLEM", 69, 80], ["biosecurity education", "TREATMENT", 229, 250], ["region", "ANATOMY_MODIFIER", 7, 13], ["clear", "OBSERVATION_MODIFIER", 31, 36], ["differences", "OBSERVATION_MODIFIER", 37, 48], ["disease", "OBSERVATION", 73, 80]]], ["In Brazil, the poorly-urbanized neighborhoods on the margins of city centers, the so called favelas, are focal points for the disease, with precarious living conditions and high population density making social distancing a near-impossibility [8] .", [["the disease", "PROBLEM", 122, 133], ["precarious living conditions", "PROBLEM", 140, 168]]]], "3afe63d6233d0ab45177d612675e889001d7b543": [["the threshold for percolation and thus also promotes the global contagion on networks with this property 5 .", [["percolation", "TREATMENT", 18, 29]]], ["We here built on this earlier modeling work for epidemics on small-world networks.", [["epidemics", "PROBLEM", 48, 57]]], ["We assume a network of nodes which are inhabited by individuals (hosts of the pathogen).", [["nodes", "ANATOMY", 23, 28], ["nodes", "MULTI-TISSUE_STRUCTURE", 23, 28], ["a network of nodes", "PROBLEM", 10, 28], ["nodes", "OBSERVATION", 23, 28]]], ["Because of transport of individuals between nodes, infecting agents can travel with them to a connected node and infect the node's community.", [["nodes", "ANATOMY", 44, 49], ["node", "ANATOMY", 104, 108], ["node", "ANATOMY", 124, 128], ["nodes", "MULTI-TISSUE_STRUCTURE", 44, 49], ["node", "MULTI-TISSUE_STRUCTURE", 104, 108], ["node", "MULTI-TISSUE_STRUCTURE", 124, 128], ["transport of individuals between nodes", "PROBLEM", 11, 49], ["infecting agents", "TREATMENT", 51, 67], ["a connected node", "PROBLEM", 92, 108], ["nodes", "OBSERVATION", 44, 49], ["node", "OBSERVATION", 104, 108], ["node", "ANATOMY", 124, 128]]], ["This process is modeled here by the established Susceptible-Infected-Recovered (SIR) model in which, for simplicity, individuals at each node are collectively in one of three states: susceptible (S), infected (I), or recovered or removed (R).", [["node", "ANATOMY", 137, 141], ["node", "MULTI-TISSUE_STRUCTURE", 137, 141], ["individuals at each node", "PROBLEM", 117, 141], ["Infected", "OBSERVATION", 60, 68], ["node", "OBSERVATION", 137, 141], ["susceptible", "OBSERVATION_MODIFIER", 183, 194], ["infected", "OBSERVATION", 200, 208]]]], "2680086b3fa85f0567147320813338ce31336578": [["IntroductionThe rapid spread and severity of disease caused by the virus SAR-CoV-2 highlights the need for effective control measures [1] [2] [3] .", [["The rapid spread", "PROBLEM", 12, 28], ["disease", "PROBLEM", 45, 52], ["the virus SAR", "PROBLEM", 63, 76], ["CoV", "TEST", 77, 80], ["effective control measures", "TREATMENT", 107, 133]]], ["A safe, effective, and scalable vaccine is the most promising way to limit the public-health impact of SARS-CoV-2.IntroductionInfluenza virus is a promising platform for vaccine development.", [["SARS", "DISEASE", 103, 107], ["Influenza virus", "DISEASE", 126, 141], ["SARS-CoV-2", "ORGANISM", 103, 113], ["Influenza virus", "ORGANISM", 126, 141], ["SARS-CoV", "SPECIES", 103, 111], ["Influenza virus", "SPECIES", 126, 141], ["A safe, effective, and scalable vaccine", "TREATMENT", 0, 39], ["IntroductionInfluenza virus", "PROBLEM", 114, 141], ["vaccine development", "TREATMENT", 170, 189]]], ["Attenuated influenza viruses are already used as vaccines against influenza itself [4] [5] [6] [7] .", [["influenza viruses", "DISEASE", 11, 28], ["influenza", "DISEASE", 66, 75], ["influenza viruses", "ORGANISM", 11, 28], ["[4] [5] [6] [7]", "SIMPLE_CHEMICAL", 83, 98], ["Attenuated influenza viruses", "PROBLEM", 0, 28], ["influenza itself", "PROBLEM", 66, 82], ["influenza viruses", "OBSERVATION", 11, 28]]], ["In addition, well-established influenza reverse genetics systems make it easy to incorporate foreign genes into the viral genome [8] [9] [10] [11] [12] .", [["[8] [9] [10] [11] [12]", "SIMPLE_CHEMICAL", 129, 151], ["foreign genes", "DNA", 93, 106], ["influenza reverse genetics systems", "TREATMENT", 30, 64]]], ["In pre-clinical animal models, influenza virions expressing foreign antigens induce antibodies against the causative agents of a variety of diseases, including West Nile virus, Bacillus anthracis, botulinum neurotoxin, and HIV [13] [14] [15] [16] .", [["West Nile virus", "DISEASE", 160, 175], ["influenza virions", "ORGANISM", 31, 48], ["West Nile virus", "ORGANISM", 160, 175], ["Bacillus anthracis", "ORGANISM", 177, 195], ["botulinum neurotoxin", "ORGANISM", 197, 217], ["HIV [13] [14] [15] [16]", "SIMPLE_CHEMICAL", 223, 246], ["foreign antigens", "PROTEIN", 60, 76], ["antibodies", "PROTEIN", 84, 94], ["West Nile virus", "SPECIES", 160, 175], ["Bacillus anthracis", "SPECIES", 177, 195], ["HIV", "SPECIES", 223, 226], ["West Nile virus", "SPECIES", 160, 175], ["Bacillus anthracis", "SPECIES", 177, 195], ["HIV", "SPECIES", 223, 226], ["influenza virions", "TREATMENT", 31, 48], ["foreign antigens", "TREATMENT", 60, 76], ["diseases", "PROBLEM", 140, 148], ["Bacillus anthracis", "PROBLEM", 177, 195], ["botulinum neurotoxin", "TEST", 197, 217], ["HIV", "PROBLEM", 223, 226]]], ["Intranasal infection with influenza viruses induces mucosal immune responses not only within the respiratory tract, but also in mucosal surfaces distal from the site of immunization [15] , which may prove important for SARS-CoV-2 [17] .", [["mucosal", "ANATOMY", 52, 59], ["respiratory tract", "ANATOMY", 97, 114], ["mucosal surfaces", "ANATOMY", 128, 144], ["site", "ANATOMY", 161, 165], ["infection", "DISEASE", 11, 20], ["influenza viruses", "DISEASE", 26, 43], ["influenza viruses", "ORGANISM", 26, 43], ["mucosal", "PATHOLOGICAL_FORMATION", 52, 59], ["respiratory tract", "ORGANISM_SUBDIVISION", 97, 114], ["mucosal surfaces", "TISSUE", 128, 144], ["SARS-CoV", "SPECIES", 219, 227], ["Intranasal infection", "PROBLEM", 0, 20], ["influenza viruses", "PROBLEM", 26, 43], ["mucosal immune responses", "PROBLEM", 52, 76], ["immunization", "TREATMENT", 169, 181], ["CoV", "TEST", 224, 227], ["infection", "OBSERVATION", 11, 20], ["influenza viruses", "OBSERVATION", 26, 43], ["mucosal immune", "OBSERVATION", 52, 66], ["respiratory tract", "ANATOMY", 97, 114], ["mucosal", "ANATOMY", 128, 135], ["surfaces", "ANATOMY_MODIFIER", 136, 144]]], ["Finally, there is already existing infrastructure for large-scale production of influenza virions for use in vaccines.IntroductionThe receptor binding domain (RBD) of the Spike glycoprotein is a key antigen candidate for SARS-CoV-2 vaccines [18] [19] [20] [21] [22] [23] .", [["influenza", "ORGANISM", 80, 89], ["Spike glycoprotein", "GENE_OR_GENE_PRODUCT", 171, 189], ["[18] [19] [20] [21] [22] [23]", "SIMPLE_CHEMICAL", 241, 270], ["receptor binding domain", "PROTEIN", 134, 157], ["RBD", "PROTEIN", 159, 162], ["Spike glycoprotein", "PROTEIN", 171, 189], ["influenza virions", "PROBLEM", 80, 97], ["The receptor binding domain (RBD)", "TREATMENT", 130, 163], ["the Spike glycoprotein", "TREATMENT", 167, 189], ["SARS", "PROBLEM", 221, 225], ["CoV", "TEST", 226, 229], ["infrastructure", "OBSERVATION", 35, 49], ["large", "OBSERVATION_MODIFIER", 54, 59], ["-scale", "OBSERVATION_MODIFIER", 59, 65], ["influenza virions", "OBSERVATION", 80, 97]]], ["Many of the most potent neutralizing antibodies against SARS-CoV-2 target the RBD [19, [24] [25] [26] [27] .", [["SARS-CoV-2", "ORGANISM", 56, 66], ["[24] [25] [26] [27]", "SIMPLE_CHEMICAL", 87, 106], ["neutralizing antibodies", "PROTEIN", 24, 47], ["RBD", "PROTEIN", 78, 81], ["SARS-CoV", "SPECIES", 56, 64], ["neutralizing antibodies", "TEST", 24, 47], ["SARS", "TEST", 56, 60], ["CoV", "TEST", 61, 64], ["the RBD", "TEST", 74, 81], ["most potent", "OBSERVATION_MODIFIER", 12, 23]]], ["Also, RBD is small in size (~200 aa), folds autonomously, and is therefore an attractive candidate for protein subunit-based approaches to vaccination for SARS-CoV-2 [19] .IntroductionHere, we have incorporated a membrane-anchored form of the SARS-CoV-2 Spike RBD into the genome of an attenuated influenza A virus.", [["membrane", "ANATOMY", 213, 221], ["RBD", "DISEASE", 6, 9], ["SARS", "DISEASE", 155, 159], ["influenza A virus", "DISEASE", 297, 314], ["SARS-CoV", "ORGANISM", 155, 163], ["membrane", "CELLULAR_COMPONENT", 213, 221], ["influenza A virus", "ORGANISM", 297, 314], ["RBD", "PROTEIN", 6, 9], ["protein subunit", "PROTEIN", 103, 118], ["SARS-CoV-2 Spike RBD", "PROTEIN", 243, 263], ["influenza A virus", "SPECIES", 297, 314], ["SARS-CoV", "SPECIES", 155, 163], ["influenza A virus", "SPECIES", 297, 314], ["RBD", "PROBLEM", 6, 9], ["small in size", "PROBLEM", 13, 26], ["protein subunit", "TREATMENT", 103, 118], ["SARS", "TEST", 155, 159], ["CoV", "TEST", 160, 163], ["a membrane", "TREATMENT", 211, 221], ["the SARS", "TEST", 239, 247], ["CoV", "TEST", 248, 251], ["Spike RBD", "PROBLEM", 254, 263], ["an attenuated influenza A virus", "PROBLEM", 283, 314], ["RBD", "OBSERVATION", 6, 9], ["small", "OBSERVATION_MODIFIER", 13, 18], ["size", "OBSERVATION_MODIFIER", 22, 26], ["attenuated", "OBSERVATION_MODIFIER", 286, 296], ["influenza", "OBSERVATION", 297, 306]]], ["Cells infected with the resulting virus express high levels of RBD on their surface.", [["Cells", "ANATOMY", 0, 5], ["surface", "ANATOMY", 76, 83], ["Cells", "CELL", 0, 5], ["RBD", "GENE_OR_GENE_PRODUCT", 63, 66], ["surface", "CELLULAR_COMPONENT", 76, 83], ["RBD", "PROTEIN", 63, 66], ["Cells infected", "PROBLEM", 0, 14], ["the resulting virus", "PROBLEM", 20, 39], ["RBD", "PROBLEM", 63, 66], ["RBD", "OBSERVATION", 63, 66]]], ["Inoculation of mice with the virus induces substantial titers of neutralizing penicillin/ml, and 100 \u00b5g of streptomycin/ml).", [["penicillin", "CHEMICAL", 78, 88], ["streptomycin", "CHEMICAL", 107, 119], ["penicillin", "CHEMICAL", 78, 88], ["streptomycin", "CHEMICAL", 107, 119], ["mice", "ORGANISM", 15, 19], ["penicillin", "SIMPLE_CHEMICAL", 78, 88], ["streptomycin", "SIMPLE_CHEMICAL", 107, 119], ["mice", "SPECIES", 15, 19], ["mice", "SPECIES", 15, 19], ["the virus", "TREATMENT", 25, 34], ["neutralizing penicillin/ml", "TREATMENT", 65, 91], ["streptomycin", "TREATMENT", 107, 119]]], ["The next day, 200 ng of each plasmid was transfected into the cells using the BioT transfection reagent (Bioland, B01-02).", [["plasmid", "ANATOMY", 29, 36], ["cells", "ANATOMY", 62, 67], ["cells", "CELL", 62, 67], ["each plasmid", "TREATMENT", 24, 36], ["the BioT transfection reagent", "TREATMENT", 74, 103], ["Bioland", "TEST", 105, 112], ["B01", "TEST", 114, 117]]], ["Then, 12-18 hours post transfection (hpt), medium was changed to influenza growth media (IGM; Opti-MEM supplemented with 0.01% heat-inactivated FBS, 0.3% bovine serum albumin [BSA] , 100 U of penicillin/ml, 100 \u00b5g of streptomycin/ml, and 100 \u00b5g of calcium chloride/ml).", [["FBS", "ANATOMY", 144, 147], ["serum", "ANATOMY", 161, 166], ["penicillin", "CHEMICAL", 192, 202], ["streptomycin", "CHEMICAL", 217, 229], ["calcium chloride", "CHEMICAL", 248, 264], ["penicillin", "CHEMICAL", 192, 202], ["streptomycin", "CHEMICAL", 217, 229], ["calcium chloride", "CHEMICAL", 248, 264], ["FBS", "ORGANISM_SUBSTANCE", 144, 147], ["bovine", "ORGANISM", 154, 160], ["serum", "ORGANISM_SUBSTANCE", 161, 166], ["albumin", "SIMPLE_CHEMICAL", 167, 174], ["BSA", "SIMPLE_CHEMICAL", 176, 179], ["penicillin", "SIMPLE_CHEMICAL", 192, 202], ["streptomycin", "SIMPLE_CHEMICAL", 217, 229], ["calcium chloride", "SIMPLE_CHEMICAL", 248, 264], ["bovine", "SPECIES", 154, 160], ["bovine", "SPECIES", 154, 160], ["influenza growth media", "PROBLEM", 65, 87], ["IGM", "TEST", 89, 92], ["Opti-MEM", "TREATMENT", 94, 102], ["FBS", "TEST", 144, 147], ["serum albumin", "TEST", 161, 174], ["BSA", "TEST", 176, 179], ["penicillin", "TREATMENT", 192, 202], ["streptomycin", "TREATMENT", 217, 229], ["calcium chloride", "TREATMENT", 248, 264]]], ["Viral supernatants were collected approximately 72 hpt and titer was determined by fifty-percent tissue culture infective dose (TCID50).IntroductionTo generate inoculum for murine infections, viruses were expanded in low serum media.", [["supernatants", "ANATOMY", 6, 18], ["tissue", "ANATOMY", 97, 103], ["serum", "ANATOMY", 221, 226], ["murine infections", "DISEASE", 173, 190], ["Viral", "ORGANISM", 0, 5], ["tissue", "TISSUE", 97, 103], ["murine", "ORGANISM", 173, 179], ["serum", "ORGANISM_SUBSTANCE", 221, 226], ["murine", "SPECIES", 173, 179], ["Viral supernatants", "TEST", 0, 18], ["murine infections", "PROBLEM", 173, 190], ["viruses", "PROBLEM", 192, 199], ["low serum media", "PROBLEM", 217, 232], ["inoculum", "OBSERVATION_MODIFIER", 160, 168]]], ["We infected MDCK-SIAT1-TMPRSS-2 cells at a low multiplicity of infection (MOI = 0.02 TCID50).", [["MDCK-SIAT1-TMPRSS-2 cells", "ANATOMY", 12, 37], ["infection", "DISEASE", 63, 72], ["MDCK-SIAT1-TMPRSS-2 cells", "CELL", 12, 37], ["MDCK-SIAT1-TMPRSS-2 cells", "CELL_LINE", 12, 37], ["MDCK", "TEST", 12, 16], ["infection", "PROBLEM", 63, 72], ["low multiplicity", "OBSERVATION_MODIFIER", 43, 59], ["infection", "OBSERVATION", 63, 72]]], ["Media was changed to OptiMEM at 24 hours post infection (hpi) and virus was collected 48-72 hpi.", [["infection", "DISEASE", 46, 55], ["Media", "TREATMENT", 0, 5], ["infection", "PROBLEM", 46, 55], ["virus", "PROBLEM", 66, 71], ["infection", "OBSERVATION", 46, 55]]], ["Viral supernatants were clarified to remove cells by filtering through a 0.45 \u00b5M syringe filter, aliquoted, and stored at -80\u00b0 C. Viruses were titered by TCID50 prior to use in mouse experiments.", [["supernatants", "ANATOMY", 6, 18], ["cells", "ANATOMY", 44, 49], ["Viral", "ORGANISM", 0, 5], ["cells", "CELL", 44, 49], ["Viruses", "ORGANISM", 130, 137], ["mouse", "ORGANISM", 177, 182], ["mouse", "SPECIES", 177, 182], ["mouse", "SPECIES", 177, 182], ["Viral supernatants", "PROBLEM", 0, 18], ["a 0.45 \u00b5M syringe filter", "TREATMENT", 71, 95], ["C. Viruses", "PROBLEM", 127, 137], ["Viruses", "OBSERVATION", 130, 137]]], ["The \u2206NA(RBD)-Flu virus reached a titer of 1.7 x 10 4 TCID50/uL following expansion in OptiMEM.", [["\u2206NA", "GENE_OR_GENE_PRODUCT", 4, 7], ["Flu virus", "SPECIES", 13, 22], ["The \u2206NA(RBD", "TEST", 0, 11], ["Flu virus", "PROBLEM", 13, 22], ["a titer", "TEST", 31, 38]]], ["To verify that \u2206NA(RBD) was stably maintained in NA segment, RNA was extracted from viral supernatant with RNeasy kit (Qiagen), and reverse transcribed to produce cDNA (Accuscript).", [["supernatant", "ANATOMY", 90, 101], ["NA", "CHEMICAL", 16, 18], ["\u2206NA", "GENE_OR_GENE_PRODUCT", 15, 18], ["NA segment", "MULTI-TISSUE_STRUCTURE", 49, 59], ["RBD", "PROTEIN", 19, 22], ["NA segment", "DNA", 49, 59], ["cDNA", "DNA", 163, 167], ["Accuscript", "DNA", 169, 179], ["RNeasy kit", "TREATMENT", 107, 117]]], ["The NA segment was amplified by PCR and visualized with a 1% agarose gel.Flow cytometry293T cells were seeded at 6 x 10 5 cells/well in a 6-well plate, 24 hours later, cells were transfected with 500 ng of either HDM-SARS-Spike-delta21 or HDM_Spike_RBD_B7-1 plasmids and 1.5 ng of Transfection Carrier DNA (Promega, E4881) using BioT reagent (Bioland Sci, B01-02), according to manufacturer's protocol.", [["293T cells", "ANATOMY", 87, 97], ["cells", "ANATOMY", 122, 127], ["cells", "ANATOMY", 168, 173], ["agarose", "SIMPLE_CHEMICAL", 61, 68], ["293T cells", "CELL", 87, 97], ["cells", "CELL", 122, 127], ["cells", "CELL", 168, 173], ["DNA", "CELLULAR_COMPONENT", 302, 305], ["NA segment", "DNA", 4, 14], ["293T cells", "CELL_LINE", 87, 97], ["HDM-SARS-Spike-delta21 or HDM_Spike_RBD_B7-1 plasmids", "DNA", 213, 266], ["Transfection Carrier DNA", "DNA", 281, 305], ["PCR", "TEST", 32, 35], ["a 1% agarose gel", "TREATMENT", 56, 72], ["Flow cytometry", "TEST", 73, 87], ["cells", "TEST", 92, 97], ["a 6-well plate", "TREATMENT", 136, 150], ["cells", "TEST", 168, 173], ["HDM", "TEST", 213, 216], ["SARS", "PROBLEM", 217, 221], ["Spike", "PROBLEM", 222, 227], ["delta21", "PROBLEM", 228, 235], ["HDM", "TEST", 239, 242], ["_Spike_RBD_B7", "TEST", 242, 255], ["1 plasmids", "TREATMENT", 256, 266], ["Transfection Carrier DNA", "TREATMENT", 281, 305], ["BioT reagent (Bioland Sci", "TREATMENT", 329, 354], ["NA segment", "ANATOMY", 4, 14]]], ["Alternatively, media was changed to IGM and cells were infected with either \u2206NA(RBD)-Flu or \u2206NA(GFP)-Flu.", [["cells", "ANATOMY", 44, 49], ["Flu", "CHEMICAL", 101, 104], ["cells", "CELL", 44, 49], ["\u2206NA(RBD)-Flu", "GENE_OR_GENE_PRODUCT", 76, 88], ["\u2206NA", "SIMPLE_CHEMICAL", 92, 95], ["GFP", "GENE_OR_GENE_PRODUCT", 96, 99], ["IGM", "CELL_TYPE", 36, 39], ["IGM and cells", "TREATMENT", 36, 49], ["Flu", "PROBLEM", 85, 88], ["NA", "TEST", 93, 95], ["GFP", "TEST", 96, 99], ["Flu", "PROBLEM", 101, 104]]], ["At 18 hpi/hpt, media was removed from cells, and cells were washed with phosphate buffered saline (PBS), dissociated from the plate with enzyme-free dissociation buffer (Thermo Fisher, 13151014), harvested by centrifugation at 1200 x g for 3 min, and washed in FACS buffer (PBS+1% Bovine Serum Albumin).", [["cells", "ANATOMY", 38, 43], ["cells", "ANATOMY", 49, 54], ["phosphate", "CHEMICAL", 72, 81], ["phosphate", "CHEMICAL", 72, 81], ["cells", "CELL", 38, 43], ["cells", "CELL", 49, 54], ["phosphate buffered saline", "SIMPLE_CHEMICAL", 72, 97], ["PBS", "SIMPLE_CHEMICAL", 99, 102], ["Bovine", "ORGANISM", 281, 287], ["Serum", "ORGANISM_SUBSTANCE", 288, 293], ["Albumin", "GENE_OR_GENE_PRODUCT", 294, 301], ["Bovine", "SPECIES", 281, 287], ["Bovine", "SPECIES", 281, 287], ["phosphate buffered saline (PBS", "TREATMENT", 72, 102], ["enzyme", "TEST", 137, 143], ["PBS", "TEST", 274, 277], ["Serum Albumin", "TEST", 288, 301]]], ["Cells were stained with either recombinant biotinylated ACE2 ectodomain (ACROBiosystems, AC2-H82E6) or CR3022 antibody (kindly provided by Neil King and Mike Murphy, University of Washington, Institute for Protein Design) for 1 hour at room temperature, washed with FACS buffer, resuspended in secondary stain, a 1:200 dilution of PE-conjugated streptavidin (Thermo Fisher, S866) or PE-conjugated Goat Anti-Human IgG (Jackson Labs, 109-115-098), and incubated on ice for 1 hour.", [["Cells", "ANATOMY", 0, 5], ["PE", "CHEMICAL", 331, 333], ["PE", "CHEMICAL", 383, 385], ["Cells", "CELL", 0, 5], ["ACE2", "GENE_OR_GENE_PRODUCT", 56, 60], ["AC2-H82E6", "GENE_OR_GENE_PRODUCT", 89, 98], ["CR3022 antibody", "GENE_OR_GENE_PRODUCT", 103, 118], ["PE-conjugated streptavidin", "SIMPLE_CHEMICAL", 331, 357], ["S866", "SIMPLE_CHEMICAL", 374, 378], ["PE", "SIMPLE_CHEMICAL", 383, 385], ["recombinant biotinylated ACE2 ectodomain", "PROTEIN", 31, 71], ["ACROBiosystems", "PROTEIN", 73, 87], ["AC2", "PROTEIN", 89, 92], ["H82E6", "PROTEIN", 93, 98], ["CR3022 antibody", "PROTEIN", 103, 118], ["conjugated Goat Anti-Human IgG", "PROTEIN", 386, 416], ["109-115-098", "PROTEIN", 432, 443], ["Goat", "SPECIES", 397, 401], ["ACROBiosystems", "TEST", 73, 87], ["AC2", "TEST", 89, 92], ["CR3022 antibody", "TEST", 103, 118], ["FACS buffer", "TREATMENT", 266, 277], ["PE", "PROBLEM", 331, 333], ["conjugated streptavidin", "TREATMENT", 334, 357], ["PE", "PROBLEM", 383, 385], ["Jackson Labs", "TEST", 418, 430], ["PE", "OBSERVATION", 331, 333], ["PE", "OBSERVATION", 383, 385]]], ["Cells were then washed twice in FACS buffer.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5]]], ["Cells infected with replicative virus were fixed in 1% paraformaldehyde in FACS buffer for 15 min on ice and washed twice more prior to FACS analysis.", [["Cells", "ANATOMY", 0, 5], ["paraformaldehyde", "CHEMICAL", 55, 71], ["Cells", "CELL", 0, 5], ["paraformaldehyde", "SIMPLE_CHEMICAL", 55, 71], ["Cells infected", "PROBLEM", 0, 14], ["replicative virus", "PROBLEM", 20, 37], ["ice", "TREATMENT", 101, 104], ["FACS analysis", "TEST", 136, 149], ["replicative virus", "OBSERVATION", 20, 37]]], ["RBD surface expression was assessed by measuring PE-positive cell populations with a BD FACSCanto II instrument.", [["surface", "ANATOMY", 4, 11], ["cell", "ANATOMY", 61, 65], ["PE", "SIMPLE_CHEMICAL", 49, 51], ["RBD", "PROTEIN", 0, 3], ["PE-positive cell populations", "CELL_LINE", 49, 77], ["RBD surface expression", "TEST", 0, 22], ["PE", "TEST", 49, 51], ["positive cell populations", "PROBLEM", 52, 77], ["a BD FACSCanto II instrument", "TREATMENT", 83, 111], ["PE", "OBSERVATION", 49, 51], ["positive cell populations", "OBSERVATION", 52, 77]]], ["For each sample, 10,000 events were collected, data shown was gated to select for singleton events.", [["singleton events", "PROBLEM", 82, 98]]], ["Analysis and compensation were performed using FlowJo v10.7.", [["Analysis", "TEST", 0, 8], ["compensation", "TEST", 13, 25], ["FlowJo v", "TEST", 47, 55]]], ["Histograms shown are for a single well of stained cells.", [["cells", "ANATOMY", 50, 55], ["cells", "CELL", 50, 55], ["stained cells", "CELL_TYPE", 42, 55], ["Histograms", "TEST", 0, 10], ["a single well of stained cells", "PROBLEM", 25, 55]]], ["However, verification of surface expression of RBD upon infection with \u0394NA(RBD)-Flu was replicated on a separate day.Animal studiesSeven week old female BALB/c mice (Jackson Labs) anesthetized intraperitonially with 100mg/kg of ketamine + 10mg/kg of xylazine in PBS and infected intranasally with 50ul of either a high (8 x 10 5 TCID50) or low (8 x 10 4 TCID50) dose of \u0394NA(RBD)-Flu, or with \u0394NA(GFP)-Flu virus (8 x 10 4 TCID50), or mock infected with OptiMEM.", [["surface", "ANATOMY", 25, 32], ["intranasally", "ANATOMY", 279, 291], ["infection", "DISEASE", 56, 65], ["ketamine", "CHEMICAL", 228, 236], ["xylazine", "CHEMICAL", 250, 258], ["\u0394NA", "CHEMICAL", 370, 373], ["ketamine", "CHEMICAL", 228, 236], ["xylazine", "CHEMICAL", 250, 258], ["surface", "CELLULAR_COMPONENT", 25, 32], ["RBD", "GENE_OR_GENE_PRODUCT", 47, 50], ["BALB/c mice", "ORGANISM", 153, 164], ["Jackson Labs", "ORGANISM", 166, 178], ["ketamine", "SIMPLE_CHEMICAL", 228, 236], ["xylazine", "SIMPLE_CHEMICAL", 250, 258], ["\u0394NA", "SIMPLE_CHEMICAL", 370, 373], ["GFP)-Flu virus", "ORGANISM", 396, 410], ["RBD", "PROTEIN", 47, 50], ["RBD", "PROTEIN", 75, 78], ["mice", "SPECIES", 160, 164], ["mice", "SPECIES", 160, 164], ["RBD", "PROBLEM", 47, 50], ["infection", "PROBLEM", 56, 65], ["\u0394NA(RBD)", "PROBLEM", 71, 79], ["Flu", "PROBLEM", 80, 83], ["Animal studies", "TEST", 117, 131], ["ketamine", "TREATMENT", 228, 236], ["xylazine", "TREATMENT", 250, 258], ["PBS", "TREATMENT", 262, 265], ["\u0394NA", "TEST", 370, 373], ["RBD", "TEST", 374, 377], ["Flu", "PROBLEM", 379, 382], ["\u0394NA", "TEST", 392, 395], ["GFP", "TEST", 396, 399], ["Flu virus", "PROBLEM", 401, 410], ["RBD", "OBSERVATION", 47, 50], ["infection", "OBSERVATION", 56, 65]]], ["Four animals were inoculated per condition.", [["animals", "ORGANISM", 5, 12]]], ["At 14-and 21-days post-infection, blood was collected from mice by retro-orbital bleed and/or cardiac puncture at the terminal time point.", [["blood", "ANATOMY", 34, 39], ["retro-orbital", "ANATOMY", 67, 80], ["cardiac", "ANATOMY", 94, 101], ["infection", "DISEASE", 23, 32], ["retro-orbital bleed", "DISEASE", 67, 86], ["blood", "ORGANISM_SUBSTANCE", 34, 39], ["mice", "ORGANISM", 59, 63], ["retro-orbital", "ORGANISM_SUBDIVISION", 67, 80], ["cardiac puncture", "MULTI-TISSUE_STRUCTURE", 94, 110], ["mice", "SPECIES", 59, 63], ["mice", "SPECIES", 59, 63], ["post-infection", "PROBLEM", 18, 32], ["retro-orbital bleed", "PROBLEM", 67, 86], ["cardiac puncture", "TEST", 94, 110], ["infection", "OBSERVATION", 23, 32], ["retro-orbital", "ANATOMY", 67, 80], ["bleed", "OBSERVATION", 81, 86], ["cardiac", "ANATOMY", 94, 101], ["puncture", "OBSERVATION", 102, 110]]], ["Blood samples clotted at room temperature for 30-60 minutes and then were centrifuged at 1000 x g for 10 min at 4\u00b0 C to separate the cellular debris and plasminogen from the sera.", [["Blood samples", "ANATOMY", 0, 13], ["cellular debris", "ANATOMY", 133, 148], ["sera", "ANATOMY", 174, 178], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["C", "GENE_OR_GENE_PRODUCT", 115, 116], ["cellular", "CELL", 133, 141], ["plasminogen", "GENE_OR_GENE_PRODUCT", 153, 164], ["sera", "ORGANISM_SUBSTANCE", 174, 178], ["plasminogen", "PROTEIN", 153, 164], ["Blood samples", "TEST", 0, 13], ["the cellular debris", "PROBLEM", 129, 148], ["plasminogen from the sera", "TEST", 153, 178], ["cellular", "OBSERVATION_MODIFIER", 133, 141], ["debris", "OBSERVATION", 142, 148]]], ["Sera was stored at -80\u00b0 C until use.", [["Sera", "ANATOMY", 0, 4], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["Sera", "TEST", 0, 4]]], ["Animal work was approved under Fred Hutchinson Cancer Research Center IACUC protocol (1893).Spike Pseudotyped Lentivirus Neutralization assaysSARS-CoV-2 spike-pseudotyped lentivirus neutralization assays were performed as previously described [33, 35] , with slight modifications.", [["Cancer", "DISEASE", 47, 53], ["Lentivirus", "ORGANISM", 110, 120], ["pseudotyped", "ORGANISM", 159, 170], ["lentivirus", "ORGANISM", 171, 181], ["lentivirus", "SPECIES", 171, 181], ["Spike", "TEST", 92, 97], ["Pseudotyped Lentivirus", "TEST", 98, 120], ["assaysSARS", "TEST", 136, 146], ["CoV", "TEST", 147, 150], ["pseudotyped lentivirus neutralization assays", "TEST", 159, 203], ["slight modifications", "PROBLEM", 259, 279], ["slight", "OBSERVATION_MODIFIER", 259, 265], ["modifications", "OBSERVATION", 266, 279]]], ["The Spike protein of SARS-CoV-2 that was used to produce pseudotyped lentivirus contained a cytoplasmic tail truncation that removes the last 21 amino acids [33] .", [["cytoplasmic", "ANATOMY", 92, 103], ["amino acids", "CHEMICAL", 145, 156], ["amino acids", "CHEMICAL", 145, 156], ["Spike", "GENE_OR_GENE_PRODUCT", 4, 9], ["SARS-CoV-2", "ORGANISM", 21, 31], ["pseudotyped", "ORGANISM", 57, 68], ["lentivirus", "ORGANISM", 69, 79], ["cytoplasmic", "ORGANISM_SUBSTANCE", 92, 103], ["amino acids", "AMINO_ACID", 145, 156], ["Spike protein", "PROTEIN", 4, 17], ["cytoplasmic tail truncation", "PROTEIN", 92, 119], ["SARS-CoV", "SPECIES", 21, 29], ["The Spike protein", "TEST", 0, 17], ["SARS", "PROBLEM", 21, 25], ["CoV", "TEST", 26, 29], ["pseudotyped lentivirus", "PROBLEM", 57, 79], ["a cytoplasmic tail truncation", "PROBLEM", 90, 119], ["amino acids", "TEST", 145, 156], ["cytoplasmic tail truncation", "OBSERVATION", 92, 119]]], ["Infections of 293T-ACE2 cells were performed in poly-L-lysine coated plates.", [["293T-ACE2 cells", "ANATOMY", 14, 29], ["poly-L-lysine", "CHEMICAL", 48, 61], ["poly-L-lysine", "CHEMICAL", 48, 61], ["293T-ACE2 cells", "CELL", 14, 29], ["poly-L-lysine", "SIMPLE_CHEMICAL", 48, 61], ["293T-ACE2 cells", "CELL_LINE", 14, 29], ["293T-ACE2 cells", "TREATMENT", 14, 29], ["poly-L-lysine coated plates", "TREATMENT", 48, 75]]], ["Sera was heat-inactivated for 30 min at 56 C immediately prior to use.", [["Sera", "ORGANISM_SUBSTANCE", 0, 4]]], ["Three-fold dilutions of sera were done starting at a 1:20 dilution.", [["sera", "ANATOMY", 24, 28], ["sera", "ORGANISM_SUBSTANCE", 24, 28], ["sera", "TEST", 24, 28]]], ["Serum was incubated with virus for 1 hr at this concentration (which was used to calculate IC50s) and then diluted 2:3 when transferred onto cells.", [["Serum", "ANATOMY", 0, 5], ["cells", "ANATOMY", 141, 146], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["cells", "CELL", 141, 146], ["virus", "PROBLEM", 25, 30]]], ["Luciferase activity was measured at 65 hpi following transfer to opaque black-bottom plates.", [["Luciferase", "GENE_OR_GENE_PRODUCT", 0, 10], ["Luciferase activity", "TEST", 0, 19], ["opaque black-bottom plates", "TREATMENT", 65, 91]]], ["Samples were run in duplicate and each plate included no-serum and no-virus controls.", [["Samples", "ANATOMY", 0, 7], ["no-serum", "ANATOMY", 54, 62], ["Samples", "TEST", 0, 7]]], ["The fraction infectivity was calculated by normalizing the luciferase reading for each sample by the average of two no-serum control wells in the same row.", [["luciferase", "GENE_OR_GENE_PRODUCT", 59, 69], ["luciferase", "PROTEIN", 59, 69], ["The fraction infectivity", "PROBLEM", 0, 24], ["-serum control wells", "TREATMENT", 118, 138], ["fraction", "OBSERVATION_MODIFIER", 4, 12], ["infectivity", "OBSERVATION", 13, 24]]], ["All neutralization curves show the mean and standard error of duplicate curves run on the same 96-well plate.", [["All neutralization curves", "TEST", 0, 25], ["duplicate curves run", "TEST", 62, 82]]], ["Neutralization curves were plotted using the neutcurve Python package (https://jbloomlab.github.io/neutcurve/, 0.3.1), which fits a two-parameter Hill curve, with the top baseline fixed to one and the bottom baseline fixed to zero.Influenza Neutralization AssaysSera were treated with receptor-destroying enzyme (RDE) to ensure that virus would not bind to residual sialic acids present in the serum.", [["serum", "ANATOMY", 394, 399], ["sialic acids", "CHEMICAL", 366, 378], ["sialic acids", "CHEMICAL", 366, 378], ["RDE", "SIMPLE_CHEMICAL", 313, 316], ["sialic acids", "SIMPLE_CHEMICAL", 366, 378], ["serum", "ORGANISM_SUBSTANCE", 394, 399], ["receptor-destroying enzyme", "PROTEIN", 285, 311], ["RDE", "PROTEIN", 313, 316], ["Influenza", "SPECIES", 231, 240], ["Neutralization curves", "TEST", 0, 21], ["the neutcurve Python package", "TREATMENT", 41, 69], ["Hill curve", "TEST", 146, 156], ["Influenza Neutralization AssaysSera", "TREATMENT", 231, 266], ["receptor-destroying enzyme", "TREATMENT", 285, 311], ["virus", "PROBLEM", 333, 338], ["residual sialic acids", "PROBLEM", 357, 378], ["sialic acids", "OBSERVATION", 366, 378]]], ["One vial of lyophilized RDE II (Seiken, 370013) was first resuspended in 20 mL PBS.", [["RDE II", "CHEMICAL", 24, 30], ["Seiken, 370013", "CHEMICAL", 32, 46], ["Seiken, 370013", "CHEMICAL", 32, 46], ["RDE II", "SIMPLE_CHEMICAL", 24, 30]]], ["We then incubated 10 \u03bcL of serum with 30 \u03bcL of RDE solution at 37\u00b0C for 3 hrs, heat-inactivated the serum and RDE by incubating at 56\u00b0C for 30 min, and centrifuged the serum at 6,000 x g for 2 min to pellet any precipitated material and collected the supernatant.", [["serum", "ANATOMY", 27, 32], ["serum", "ANATOMY", 100, 105], ["serum", "ANATOMY", 168, 173], ["supernatant", "ANATOMY", 251, 262], ["RDE", "CHEMICAL", 47, 50], ["RDE", "CHEMICAL", 110, 113], ["serum", "ORGANISM_SUBSTANCE", 27, 32], ["RDE", "SIMPLE_CHEMICAL", 47, 50], ["serum", "ORGANISM_SUBSTANCE", 100, 105], ["RDE", "SIMPLE_CHEMICAL", 110, 113], ["serum", "ORGANISM_SUBSTANCE", 168, 173], ["serum", "TEST", 27, 32], ["RDE solution", "TREATMENT", 47, 59], ["the serum", "TEST", 96, 105]]], ["Neutralization was measured against virus containing H3 from A/Aichi/2/1968 virus with two mutations Y98F and G379W, carrying GFP in the PB1 segment, and all other internal genes from A/WSN/33.", [["H3", "GENE_OR_GENE_PRODUCT", 53, 55], ["A/Aichi/2/1968 virus", "ORGANISM", 61, 81], ["GFP", "GENE_OR_GENE_PRODUCT", 126, 129], ["GFP", "DNA", 126, 129], ["PB1 segment", "DNA", 137, 148], ["internal genes", "DNA", 164, 178], ["A/Aichi/2/1968 virus", "SPECIES", 61, 81], ["A/WSN/33", "SPECIES", 184, 192], ["Neutralization", "TREATMENT", 0, 14], ["virus", "PROBLEM", 36, 41], ["H3", "PROBLEM", 53, 55], ["carrying GFP in the PB1 segment", "PROBLEM", 117, 148], ["PB1", "ANATOMY", 137, 140], ["segment", "ANATOMY_MODIFIER", 141, 148], ["internal genes", "ANATOMY", 164, 178]]], ["The neutralization assays were performed in MDCK-SIAT1-CMV-PB1 cells using this GFP-expressing virus as described previously [36] [37] [38] [39] .", [["MDCK-SIAT1-CMV-PB1 cells", "ANATOMY", 44, 68], ["MDCK-SIAT1-CMV-PB1 cells", "CELL", 44, 68], ["GFP", "GENE_OR_GENE_PRODUCT", 80, 83], ["MDCK-SIAT1-CMV-PB1 cells", "CELL_LINE", 44, 68], ["GFP", "PROTEIN", 80, 83], ["The neutralization assays", "TEST", 0, 25], ["MDCK", "TEST", 44, 48], ["SIAT1", "TEST", 49, 54], ["this GFP", "TEST", 75, 83], ["expressing virus", "PROBLEM", 84, 100]]], ["As with Spike pseudotyped lentivirus neutralization assays, curves were plotted and IC50s were calculated using the neutcurve Python package.Engineering and characterization of influenza virus encoding SARS-CoV-2 RBDWe set out to incorporate a membrane-anchored form of the receptor binding domain (RBD) of SARS-CoV-2 Spike into the influenza genome.", [["membrane", "ANATOMY", 244, 252], ["Spike pseudotyped", "ORGANISM", 8, 25], ["lentivirus", "ORGANISM", 26, 36], ["influenza virus", "ORGANISM", 177, 192], ["SARS-CoV-2", "ORGANISM", 202, 212], ["membrane", "CELLULAR_COMPONENT", 244, 252], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 307, 317], ["SARS-CoV-2 RBDWe", "DNA", 202, 218], ["membrane-anchored form", "PROTEIN", 244, 266], ["receptor binding domain", "PROTEIN", 274, 297], ["RBD", "PROTEIN", 299, 302], ["SARS-CoV-2 Spike", "DNA", 307, 323], ["influenza genome", "DNA", 333, 349], ["influenza virus", "SPECIES", 177, 192], ["lentivirus", "SPECIES", 26, 36], ["influenza virus", "SPECIES", 177, 192], ["SARS-CoV", "SPECIES", 202, 210], ["Spike pseudotyped lentivirus neutralization assays", "PROBLEM", 8, 58], ["curves", "TEST", 60, 66], ["IC50s", "TEST", 84, 89], ["the neutcurve Python package", "TREATMENT", 112, 140], ["influenza virus encoding SARS", "PROBLEM", 177, 206], ["CoV", "TEST", 207, 210], ["SARS", "PROBLEM", 307, 311], ["CoV", "TEST", 312, 315], ["the influenza genome", "PROBLEM", 329, 349], ["influenza genome", "OBSERVATION", 333, 349]]], ["To enable cell-surface display of the RBD protein, we appended a mammalian signal peptide to the N-terminus of the RBD and a transmembrane region and cytoplasmic domain from murine B7.1 to the C-terminus of the RBD.", [["cell", "ANATOMY", 10, 14], ["surface", "ANATOMY", 15, 22], ["transmembrane", "ANATOMY", 125, 138], ["cytoplasmic", "ANATOMY", 150, 161], ["RBD", "DISEASE", 211, 214], ["N", "CHEMICAL", 97, 98], ["cell", "CELL", 10, 14], ["surface", "CELLULAR_COMPONENT", 15, 22], ["RBD", "GENE_OR_GENE_PRODUCT", 115, 118], ["transmembrane", "CELLULAR_COMPONENT", 125, 138], ["cytoplasmic", "ORGANISM_SUBSTANCE", 150, 161], ["murine", "ORGANISM", 174, 180], ["B7.1", "GENE_OR_GENE_PRODUCT", 181, 185], ["RBD protein", "PROTEIN", 38, 49], ["N-terminus", "PROTEIN", 97, 107], ["RBD", "PROTEIN", 115, 118], ["transmembrane region", "PROTEIN", 125, 145], ["cytoplasmic domain", "PROTEIN", 150, 168], ["murine B7.1", "PROTEIN", 174, 185], ["C-terminus", "PROTEIN", 193, 203], ["RBD", "PROTEIN", 211, 214], ["murine", "SPECIES", 174, 180], ["the RBD protein", "TEST", 34, 49], ["a mammalian signal peptide", "PROBLEM", 63, 89], ["a transmembrane region", "TREATMENT", 123, 145], ["cytoplasmic domain", "TEST", 150, 168], ["RBD", "ANATOMY", 115, 118], ["RBD", "OBSERVATION", 211, 214]]], ["The murine B7.1 sequence was used as it has previously been shown to induce high levels of surface expression of chimeric proteins [29] .", [["surface", "ANATOMY", 91, 98], ["murine", "ORGANISM", 4, 10], ["B7.1", "GENE_OR_GENE_PRODUCT", 11, 15], ["murine B7.1 sequence", "DNA", 4, 24], ["chimeric proteins", "PROTEIN", 113, 130], ["murine", "SPECIES", 4, 10], ["The murine B7.1 sequence", "TEST", 0, 24], ["chimeric proteins", "TEST", 113, 130]]], ["We engineered the neuraminidase (NA) segment of the A/WSN/33 influenza virus to replace the NA coding sequence with a sequence encoding the membrane-anchored RBD and named the resulting construct \u0394NA(RBD) (Fig. 1A) .", [["membrane", "ANATOMY", 140, 148], ["A/WSN/33 influenza virus", "ORGANISM", 52, 76], ["membrane", "CELLULAR_COMPONENT", 140, 148], ["neuraminidase (NA) segment", "PROTEIN", 18, 44], ["NA coding sequence", "DNA", 92, 110], ["membrane-anchored RBD", "PROTEIN", 140, 161], ["\u0394NA", "PROTEIN", 196, 199], ["RBD", "PROTEIN", 200, 203], ["influenza virus", "SPECIES", 61, 76], ["A/WSN/33 influenza virus", "SPECIES", 52, 76], ["the A/WSN/33 influenza virus", "TREATMENT", 48, 76], ["the NA coding sequence", "TEST", 88, 110], ["anchored RBD", "PROBLEM", 149, 161]]], ["To facilitate packaging of this segment into influenza virions, the packaging signals located at the NA segment termini, which span coding and non-coding regions of vRNA, were retained ( Fig 1A) .", [["NA segment termini", "DNA", 101, 119], ["non-coding regions", "DNA", 143, 161], ["vRNA", "DNA", 165, 169], ["influenza virions", "TREATMENT", 45, 62], ["vRNA", "PROBLEM", 165, 169], ["influenza virions", "OBSERVATION", 45, 62], ["NA segment", "ANATOMY_MODIFIER", 101, 111], ["termini", "ANATOMY_MODIFIER", 112, 119], ["non-coding", "OBSERVATION_MODIFIER", 143, 153], ["regions", "OBSERVATION_MODIFIER", 154, 161], ["vRNA", "OBSERVATION_MODIFIER", 165, 169]]], ["These terminal packaging signals comprised 113 and 126 bp at the 3' and 5' ends of the vRNA, respectively [30, 31] .", [["3'", "CELLULAR_COMPONENT", 65, 67], ["5' ends", "CELLULAR_COMPONENT", 72, 79], ["3' and 5' ends", "DNA", 65, 79], ["bp", "TEST", 55, 57], ["terminal", "OBSERVATION_MODIFIER", 6, 14], ["vRNA", "OBSERVATION", 87, 91]]], ["Mutations were introduced in these regions to remove the start codons upstream of the RBD coding sequence, as well as eliminate a cryptic bacterial promoter (see plasmid map in Supplemental File 1).", [["start codons", "DNA", 57, 69], ["RBD coding sequence", "DNA", 86, 105], ["cryptic bacterial promoter", "DNA", 130, 156], ["Mutations", "PROBLEM", 0, 9], ["the RBD coding sequence", "TEST", 82, 105], ["a cryptic bacterial promoter", "TREATMENT", 128, 156]]], ["Restriction sites were inserted immediately adjacent to the NA packaging signal on both the 5' and the 3' ends of the coding sequence.", [["3' ends", "CELLULAR_COMPONENT", 103, 110], ["NA packaging signal", "DNA", 60, 79], ["5' and the 3' ends", "DNA", 92, 110], ["coding sequence", "DNA", 118, 133], ["Restriction sites", "PROBLEM", 0, 17], ["NA packaging", "OBSERVATION", 60, 72]]], ["We used reverse-genetics to generate influenza virions encoding the \u0394NA(RBD) segment and named the resulting virus \u0394NA(RBD)-Flu.", [["\u0394NA(RBD) segment", "PROTEIN", 68, 84], ["RBD", "PROTEIN", 119, 122], ["influenza virions", "TREATMENT", 37, 54], ["the resulting virus \u0394NA", "PROBLEM", 95, 118], ["Flu", "PROBLEM", 124, 127]]], ["In addition to the \u0394NA(RBD) segment, these viruses contained the hemagglutinin (HA) segment from the A/Aichi/2/1968 (H3N2) strain with an amino acid mutation (Y98F) that reduces affinity for HA's sialic acid receptor [40] .", [["amino acid", "CHEMICAL", 138, 148], ["sialic acid", "CHEMICAL", 196, 207], ["amino acid", "CHEMICAL", 138, 148], ["sialic acid", "CHEMICAL", 196, 207], ["A/Aichi/2/1968 (H3N2) strain", "ORGANISM", 101, 129], ["amino acid", "AMINO_ACID", 138, 148], ["HA's sialic acid receptor", "GENE_OR_GENE_PRODUCT", 191, 216], ["\u0394NA(RBD) segment", "DNA", 19, 35], ["hemagglutinin (HA) segment", "PROTEIN", 65, 91], ["HA", "PROTEIN", 191, 193], ["sialic acid receptor", "PROTEIN", 196, 216], ["A/Aichi/2/1968 (H3N2)", "SPECIES", 101, 122], ["the \u0394NA(RBD) segment", "PROBLEM", 15, 35], ["these viruses", "PROBLEM", 37, 50], ["the hemagglutinin (HA) segment", "PROBLEM", 61, 91], ["H3N2", "PROBLEM", 117, 121], ["an amino acid mutation", "TEST", 135, 157], ["HA's sialic acid receptor", "TREATMENT", 191, 216], ["viruses", "OBSERVATION", 43, 50], ["hemagglutinin", "OBSERVATION_MODIFIER", 65, 78]]], ["The Y98F mutation was included for two reasons: first, we anticipated that it would improve the growth of viruses that lacked a NA, which typically counterbalances HA's receptor-binding activity [36, 40] ; and second, because viruses with this mutation are known to be severely attenuated in mice [4] .", [["NA", "CHEMICAL", 128, 130], ["Y98F", "GENE_OR_GENE_PRODUCT", 4, 8], ["mice", "ORGANISM", 292, 296], ["Y98F", "DNA", 4, 8], ["mice", "SPECIES", 292, 296], ["mice", "SPECIES", 292, 296], ["The Y98F mutation", "PROBLEM", 0, 17], ["the growth of viruses", "PROBLEM", 92, 113], ["a NA", "PROBLEM", 126, 130], ["viruses", "PROBLEM", 226, 233], ["this mutation", "PROBLEM", 239, 252]]], ["The remaining influenza genes of \u0394NA(RBD)-Flu were derived from the mouse-and lab-adapted strain A/WSN/33 (H1N1) strain.", [["\u0394NA(RBD)-Flu", "GENE_OR_GENE_PRODUCT", 33, 45], ["mouse", "ORGANISM", 68, 73], ["A/WSN/33 (H1N1)", "ORGANISM", 97, 112], ["strain", "ORGANISM", 113, 119], ["influenza genes", "DNA", 14, 29], ["\u0394NA", "DNA", 33, 36], ["RBD", "DNA", 37, 40], ["mouse", "SPECIES", 68, 73], ["mouse", "SPECIES", 68, 73], ["A/WSN/33 (H1N1)", "SPECIES", 97, 112], ["The remaining influenza genes of \u0394NA", "PROBLEM", 0, 36], ["Flu", "PROBLEM", 42, 45], ["strain", "PROBLEM", 113, 119], ["influenza genes", "OBSERVATION", 14, 29]]], ["The viral supernatant from reverse genetics was blind passaged twice in MDCK-SIAT1-TMPRSS2 cells at three-day intervals.", [["supernatant", "ANATOMY", 10, 21], ["MDCK-SIAT1-TMPRSS2 cells", "ANATOMY", 72, 96], ["MDCK-SIAT1-TMPRSS2 cells", "CELL", 72, 96], ["MDCK", "CELL_LINE", 72, 76], ["SIAT1", "CELL_LINE", 77, 82], ["TMPRSS2 cells", "CELL_LINE", 83, 96], ["The viral supernatant", "PROBLEM", 0, 21], ["MDCK", "TEST", 72, 76], ["viral supernatant", "OBSERVATION", 4, 21]]], ["Upon the final passage, cytopathic effect was evident in the well containing \u0394NA(RBD)-Flu, suggesting the presence of replicating virus.Engineering and characterization of influenza virus encoding SARS-CoV-2 RBDNext, we verified that the RBD sequence was stably maintained in the NA segment.", [["influenza virus", "ORGANISM", 172, 187], ["SARS-CoV-2", "ORGANISM", 197, 207], ["RBDNext", "ORGANISM", 208, 215], ["RBD", "PROTEIN", 81, 84], ["SARS-CoV-2 RBDNext", "DNA", 197, 215], ["RBD sequence", "DNA", 238, 250], ["NA segment", "DNA", 280, 290], ["influenza virus", "SPECIES", 172, 187], ["influenza virus", "SPECIES", 172, 187], ["cytopathic effect", "PROBLEM", 24, 41], ["Flu", "PROBLEM", 86, 89], ["replicating virus", "PROBLEM", 118, 135], ["influenza virus", "PROBLEM", 172, 187], ["the RBD sequence", "TEST", 234, 250], ["passage", "OBSERVATION_MODIFIER", 15, 22], ["cytopathic effect", "OBSERVATION", 24, 41], ["replicating", "OBSERVATION_MODIFIER", 118, 129], ["virus", "OBSERVATION", 130, 135], ["NA segment", "ANATOMY_MODIFIER", 280, 290]]], ["We extracted RNA from the viral supernatant from the final passage, and reverse transcribed and PCR-amplified the HA and NA segments (Fig 1B) .", [["supernatant", "ANATOMY", 32, 43], ["HA and NA segments", "DNA", 114, 132], ["extracted RNA", "PROBLEM", 3, 16], ["the viral supernatant", "PROBLEM", 22, 43], ["PCR", "TEST", 96, 99], ["viral supernatant", "OBSERVATION_MODIFIER", 26, 43], ["passage", "OBSERVATION_MODIFIER", 59, 66]]], ["The size of the NA segment isolated from \u0394NA(RBD)-Flu was consistent with the expected size of this segment.", [["NA segment", "DNA", 16, 26], ["RBD", "PROTEIN", 45, 48], ["Flu", "PROBLEM", 50, 53], ["size", "OBSERVATION_MODIFIER", 4, 8], ["NA segment", "ANATOMY_MODIFIER", 16, 26], ["consistent with", "UNCERTAINTY", 58, 73], ["size", "OBSERVATION_MODIFIER", 87, 91], ["segment", "ANATOMY_MODIFIER", 100, 107]]], ["Sanger sequencing was performed on both the NA and HA segments to identify any potential tissue-culture adaptations.", [["tissue", "ANATOMY", 89, 95], ["tissue", "TISSUE", 89, 95], ["NA and HA segments", "DNA", 44, 62], ["Sanger sequencing", "TEST", 0, 17]]], ["No mutations were identified in \u0394NA(RBD) segment.", [["\u0394NA(RBD) segment", "DNA", 32, 48], ["mutations", "PROBLEM", 3, 12], ["mutations", "OBSERVATION", 3, 12], ["segment", "ANATOMY_MODIFIER", 41, 48]]], ["However, a single amino-acid substitution was present in HA (G379W), which we speculated might aid the growth of these engineered virions.", [["virions", "ANATOMY", 130, 137], ["amino-acid", "CHEMICAL", 18, 28], ["amino-acid", "CHEMICAL", 18, 28], ["amino-acid", "SIMPLE_CHEMICAL", 18, 28], ["a single amino-acid substitution", "TREATMENT", 9, 41], ["HA", "PROBLEM", 57, 59], ["-acid substitution", "OBSERVATION", 23, 41], ["engineered virions", "OBSERVATION", 119, 137]]], ["We validated that this mutation, and an additional HA mutation isolated in a virus with no NA segment (R453G), improved titers of \u0394NA(RBD)-Flu generated by reverse genetics, although the titers were still lower than for a virus with the same HA and an intact NA segment (Fig 1C) .", [["\u0394NA(RBD)-Flu", "GENE_OR_GENE_PRODUCT", 130, 142], ["NA segment", "DNA", 91, 101], ["RBD", "PROTEIN", 134, 137], ["NA segment", "DNA", 259, 269], ["this mutation", "PROBLEM", 18, 31], ["an additional HA mutation", "PROBLEM", 37, 62], ["a virus", "PROBLEM", 75, 82], ["Flu", "PROBLEM", 139, 142], ["the titers", "TEST", 183, 193], ["a virus", "PROBLEM", 220, 227], ["the same HA", "PROBLEM", 233, 244], ["intact", "OBSERVATION", 252, 258], ["NA segment", "OBSERVATION_MODIFIER", 259, 269]]], ["The mechanism for how these mutations in HA2 might improve titers from reverse genetics is not known.", [["these mutations in HA2", "PROBLEM", 22, 44]]], ["For all subsequent experiments, the originally isolated and amplified \u0394NA(RBD)-Flu, containing H3_Y98F/G379W was used.", [["RBD", "PROTEIN", 74, 77], ["H3_Y98F", "DNA", 95, 102], ["Flu", "PROBLEM", 79, 82]]], ["As a control, we used a virus containing this HA (H3_Y98F/G379W) and GFP in the NA segment (\u0394NA(GFP)-Flu).Cells infected \u0394NA(RBD)-Flu express high levels of RBD on their surfaceWe next set out to determine if cells transfected with the membrane-anchored RBD gene or infected with \u0394NA(RBD)-Flu expressed RBD on their surface.", [["Cells", "ANATOMY", 106, 111], ["cells", "ANATOMY", 209, 214], ["membrane", "ANATOMY", 236, 244], ["surface", "ANATOMY", 316, 323], ["HA", "GENE_OR_GENE_PRODUCT", 46, 48], ["GFP", "GENE_OR_GENE_PRODUCT", 69, 72], ["Cells", "CELL", 106, 111], ["\u0394NA(RBD)-Flu", "GENE_OR_GENE_PRODUCT", 121, 133], ["cells", "CELL", 209, 214], ["membrane", "CELLULAR_COMPONENT", 236, 244], ["RBD", "GENE_OR_GENE_PRODUCT", 254, 257], ["\u0394NA(RBD)-Flu", "GENE_OR_GENE_PRODUCT", 280, 292], ["surface", "CELLULAR_COMPONENT", 316, 323], ["GFP", "PROTEIN", 69, 72], ["NA segment", "DNA", 80, 90], ["RBD", "PROTEIN", 125, 128], ["RBD", "PROTEIN", 157, 160], ["membrane-anchored RBD gene", "DNA", 236, 262], ["RBD", "PROTEIN", 284, 287], ["RBD", "PROTEIN", 303, 306], ["a virus", "PROBLEM", 22, 29], ["this HA", "PROBLEM", 41, 48], ["GFP", "TEST", 69, 72], ["\u0394NA", "TEST", 92, 95], ["GFP", "TEST", 96, 99], ["Cells infected \u0394NA(RBD)", "PROBLEM", 106, 129], ["Flu express high levels of RBD", "PROBLEM", 130, 160], ["the membrane", "PROBLEM", 232, 244], ["anchored RBD gene", "PROBLEM", 245, 262], ["\u0394NA(RBD", "PROBLEM", 280, 287], ["Flu expressed RBD", "PROBLEM", 289, 306], ["NA segment", "ANATOMY", 80, 90], ["RBD", "OBSERVATION", 303, 306]]], ["To do this, we transfected cells with a mammalian protein expression plasmid encoding the membrane-anchored RBD or the SARS-CoV-2 Spike (lacking the last 21 amino acids of the cytoplasmic tail).", [["cells", "ANATOMY", 27, 32], ["membrane", "ANATOMY", 90, 98], ["cytoplasmic tail", "ANATOMY", 176, 192], ["amino acids", "CHEMICAL", 157, 168], ["amino acids", "CHEMICAL", 157, 168], ["cells", "CELL", 27, 32], ["membrane", "CELLULAR_COMPONENT", 90, 98], ["RBD", "GENE_OR_GENE_PRODUCT", 108, 111], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 119, 129], ["amino acids", "AMINO_ACID", 157, 168], ["cytoplasmic", "ORGANISM_SUBSTANCE", 176, 187], ["tail", "MULTI-TISSUE_STRUCTURE", 188, 192], ["mammalian protein expression plasmid", "DNA", 40, 76], ["membrane-anchored RBD", "PROTEIN", 90, 111], ["SARS-CoV-2 Spike", "DNA", 119, 135], ["last 21 amino acids", "PROTEIN", 149, 168], ["cytoplasmic tail", "PROTEIN", 176, 192], ["a mammalian protein expression plasmid", "TREATMENT", 38, 76], ["anchored RBD", "PROBLEM", 99, 111], ["the SARS", "TEST", 115, 123], ["CoV", "TEST", 124, 127], ["Spike", "PROBLEM", 130, 135]]], ["We also infected cells with either \u0394NA(RBD)-Flu or \u0394NA(GFP)-Flu.", [["cells", "ANATOMY", 17, 22], ["Flu", "CHEMICAL", 44, 47], ["\u0394NA", "CHEMICAL", 51, 54], ["Flu", "CHEMICAL", 60, 63], ["cells", "CELL", 17, 22], ["\u0394NA(RBD)-Flu", "GENE_OR_GENE_PRODUCT", 35, 47], ["\u0394NA(GFP)-Flu", "GENE_OR_GENE_PRODUCT", 51, 63], ["RBD", "PROTEIN", 39, 42], ["GFP", "PROTEIN", 55, 58], ["infected cells", "PROBLEM", 8, 22], ["\u0394NA(RBD)", "PROBLEM", 35, 43], ["Flu", "PROBLEM", 44, 47], ["\u0394NA", "PROBLEM", 51, 54], ["GFP", "TEST", 55, 58], ["Flu", "PROBLEM", 60, 63], ["infected cells", "OBSERVATION", 8, 22]]], ["We stained the cells with a soluble recombinant version of ACE2, the host receptor that is bound by the SARS-CoV-2 spike's RBD to mediate viral entry.", [["cells", "ANATOMY", 15, 20], ["cells", "CELL", 15, 20], ["ACE2", "GENE_OR_GENE_PRODUCT", 59, 63], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 104, 114], ["RBD", "GENE_OR_GENE_PRODUCT", 123, 126], ["ACE2", "PROTEIN", 59, 63], ["RBD", "PROTEIN", 123, 126], ["a soluble recombinant version of ACE2", "TREATMENT", 26, 63], ["the host receptor", "TREATMENT", 65, 82], ["the SARS", "TEST", 100, 108], ["CoV", "TEST", 109, 112], ["2 spike's RBD", "PROBLEM", 113, 126], ["viral entry", "OBSERVATION", 138, 149]]], ["We separately stained the cells with the antibody CR3022, which binds to the RBD in a region which does not overlap with the ACE2 binding site [41, 42] .", [["cells", "ANATOMY", 26, 31], ["cells", "CELL", 26, 31], ["CR3022", "GENE_OR_GENE_PRODUCT", 50, 56], ["ACE2", "GENE_OR_GENE_PRODUCT", 125, 129], ["antibody CR3022", "PROTEIN", 41, 56], ["RBD", "PROTEIN", 77, 80], ["ACE2 binding site", "DNA", 125, 142], ["the antibody CR3022", "TEST", 37, 56], ["RBD", "OBSERVATION", 77, 80]]], ["There were high levels of RBD expression on the surface of transfected and infected cells labeled with both ACE2 and CR3022 (Fig 2) .", [["surface", "ANATOMY", 48, 55], ["cells", "ANATOMY", 84, 89], ["RBD", "GENE_OR_GENE_PRODUCT", 26, 29], ["surface", "CELLULAR_COMPONENT", 48, 55], ["cells", "CELL", 84, 89], ["ACE2", "GENE_OR_GENE_PRODUCT", 108, 112], ["RBD", "PROTEIN", 26, 29], ["infected cells", "CELL_TYPE", 75, 89], ["ACE2", "PROTEIN", 108, 112], ["CR3022", "PROTEIN", 117, 123], ["high levels of RBD expression", "PROBLEM", 11, 40], ["infected cells", "PROBLEM", 75, 89], ["high", "OBSERVATION_MODIFIER", 11, 15], ["levels", "OBSERVATION_MODIFIER", 16, 22], ["RBD expression", "OBSERVATION", 26, 40], ["infected cells", "OBSERVATION", 75, 89]]], ["Notably, cells transfected with the membrane-anchored RBD had substantially higher staining for RBD on their surface than cells transfected with Spike, and cells infected with \u0394NA(RBD)-Flu had even higher levels of RBD than the transfected cells (Fig. 2) .Figure 2.", [["cells", "ANATOMY", 9, 14], ["membrane", "ANATOMY", 36, 44], ["surface", "ANATOMY", 109, 116], ["cells", "ANATOMY", 122, 127], ["cells", "ANATOMY", 156, 161], ["cells", "ANATOMY", 240, 245], ["cells", "CELL", 9, 14], ["membrane", "CELLULAR_COMPONENT", 36, 44], ["RBD", "GENE_OR_GENE_PRODUCT", 54, 57], ["RBD", "GENE_OR_GENE_PRODUCT", 96, 99], ["surface", "CELLULAR_COMPONENT", 109, 116], ["cells", "CELL", 122, 127], ["Spike", "GENE_OR_GENE_PRODUCT", 145, 150], ["cells", "CELL", 156, 161], ["\u0394NA(RBD)-Flu", "GENE_OR_GENE_PRODUCT", 176, 188], ["cells", "CELL", 240, 245], ["membrane-anchored RBD", "PROTEIN", 36, 57], ["RBD", "PROTEIN", 96, 99], ["Spike", "PROTEIN", 145, 150], ["RBD", "PROTEIN", 180, 183], ["RBD", "PROTEIN", 215, 218], ["transfected cells", "CELL_LINE", 228, 245], ["anchored RBD", "PROBLEM", 45, 57], ["substantially higher staining", "PROBLEM", 62, 91], ["RBD", "PROBLEM", 96, 99], ["Spike", "PROBLEM", 145, 150], ["cells infected", "PROBLEM", 156, 170], ["\u0394NA(RBD)", "PROBLEM", 176, 184], ["Flu", "PROBLEM", 185, 188], ["higher levels of RBD", "PROBLEM", 198, 218], ["the transfected cells", "PROBLEM", 224, 245], ["transfected cells", "OBSERVATION", 228, 245]]], ["Infection with \u0394NA(RBD)-Flu leads to expression of RBD on the surface of 293T cells.Histograms, normalized to mode, of flow cytometry measurements showing RBD expression on the cell surface for (A) Cells transfected with the mammalian expression plasmids HDM-SARS-Spike-delta21 or HDM_Spike_RBD_B7-1 and stained with ACE2 or (B) stained with CR3022 antibody, (C) Cells infected with \u0394NA(RBD)-Flu or \u0394NA(GFP)-Flu and stained with ACE2 or (D) CR3022 antibody.", [["surface", "ANATOMY", 62, 69], ["293T cells", "ANATOMY", 73, 83], ["cell surface", "ANATOMY", 177, 189], ["Cells", "ANATOMY", 198, 203], ["Cells", "ANATOMY", 363, 368], ["Flu", "CHEMICAL", 24, 27], ["\u0394NA(RBD)-Flu", "GENE_OR_GENE_PRODUCT", 15, 27], ["RBD", "GENE_OR_GENE_PRODUCT", 51, 54], ["surface", "CELLULAR_COMPONENT", 62, 69], ["293T cells", "CELL", 73, 83], ["cell surface", "CELLULAR_COMPONENT", 177, 189], ["Cells", "CELL", 198, 203], ["HDM_Spike_RBD_B7-1", "GENE_OR_GENE_PRODUCT", 281, 299], ["ACE2", "GENE_OR_GENE_PRODUCT", 317, 321], ["CR3022", "GENE_OR_GENE_PRODUCT", 342, 348], ["Cells", "CELL", 363, 368], ["\u0394NA(RBD)-Flu", "GENE_OR_GENE_PRODUCT", 383, 395], ["\u0394NA(GFP)-Flu", "GENE_OR_GENE_PRODUCT", 399, 411], ["ACE2", "GENE_OR_GENE_PRODUCT", 429, 433], ["(D) CR3022 antibody", "GENE_OR_GENE_PRODUCT", 437, 456], ["RBD", "PROTEIN", 19, 22], ["RBD", "PROTEIN", 51, 54], ["293T cells", "CELL_LINE", 73, 83], ["RBD", "PROTEIN", 155, 158], ["mammalian expression plasmids", "DNA", 225, 254], ["HDM", "PROTEIN", 255, 258], ["Spike", "PROTEIN", 264, 269], ["delta21", "DNA", 270, 277], ["HDM_Spike_RBD_B7-1", "DNA", 281, 299], ["ACE2", "PROTEIN", 317, 321], ["CR3022 antibody", "PROTEIN", 342, 357], ["RBD", "PROTEIN", 387, 390], ["GFP", "PROTEIN", 403, 406], ["ACE2 or (D) CR3022 antibody", "PROTEIN", 429, 456], ["Infection", "PROBLEM", 0, 9], ["\u0394NA(RBD)", "PROBLEM", 15, 23], ["Flu", "PROBLEM", 24, 27], ["RBD", "PROBLEM", 51, 54], ["Histograms", "TEST", 84, 94], ["flow cytometry measurements", "TEST", 119, 146], ["RBD expression", "PROBLEM", 155, 169], ["the cell surface", "TREATMENT", 173, 189], ["A) Cells", "TREATMENT", 195, 203], ["the mammalian expression plasmids", "TREATMENT", 221, 254], ["HDM", "TEST", 255, 258], ["SARS", "PROBLEM", 259, 263], ["Spike", "PROBLEM", 264, 269], ["delta21", "PROBLEM", 270, 277], ["HDM_Spike_RBD_B7", "TEST", 281, 297], ["ACE2", "TEST", 317, 321], ["CR3022 antibody", "TEST", 342, 357], ["(C) Cells infected", "PROBLEM", 359, 377], ["\u0394NA", "PROBLEM", 383, 386], ["RBD", "TEST", 387, 390], ["Flu", "PROBLEM", 392, 395], ["\u0394NA", "PROBLEM", 399, 402], ["GFP", "TEST", 403, 406], ["Flu", "PROBLEM", 408, 411], ["ACE2", "TEST", 429, 433], ["CR3022 antibody", "TEST", 441, 456], ["RBD", "OBSERVATION", 51, 54], ["293T cells", "OBSERVATION", 73, 83], ["RBD expression", "OBSERVATION", 155, 169]]], ["Data shown is from a single population of stained cells.\u0394NA(RBD)-Flu induces neutralizing antibodies against SARS-CoV-2 and influenza virus without causing disease in miceTo determine if the \u0394NA(RBD)-Flu virus induces an anti-RBD antibody response in vivo, we intranasally infected four groups of four mice with either a high dose (8 x 10 5 TCID50) or lower dose of \u0394NA(RBD)-Flu (8 x 10 4 TCID50), a control virus expressing GFP in the NA segment (\u0394NA(GFP)-Flu, at 8 x 10 4 TCID50), or performed a mock infection (Fig 3A) .", [["cells", "ANATOMY", 50, 55], ["\u0394NA", "CHEMICAL", 56, 59], ["Flu", "CHEMICAL", 65, 68], ["influenza virus", "DISEASE", 124, 139], ["\u0394NA", "CHEMICAL", 366, 369], ["Flu", "CHEMICAL", 375, 378], ["infection", "DISEASE", 503, 512], ["Flu", "CHEMICAL", 65, 68], ["Flu", "CHEMICAL", 375, 378], ["cells", "CELL", 50, 55], ["\u0394NA", "SIMPLE_CHEMICAL", 56, 59], ["SARS-CoV-2", "ORGANISM", 109, 119], ["influenza virus", "ORGANISM", 124, 139], ["\u0394NA(RBD)-Flu virus", "ORGANISM", 191, 209], ["mice", "ORGANISM", 302, 306], ["GFP", "GENE_OR_GENE_PRODUCT", 425, 428], ["GFP", "GENE_OR_GENE_PRODUCT", 452, 455], ["stained cells", "CELL_TYPE", 42, 55], ["RBD", "PROTEIN", 60, 63], ["neutralizing antibodies", "PROTEIN", 77, 100], ["anti-RBD antibody", "PROTEIN", 221, 238], ["GFP", "PROTEIN", 425, 428], ["NA segment", "DNA", 436, 446], ["GFP", "PROTEIN", 452, 455], ["CoV-2", "SPECIES", 114, 119], ["influenza virus", "SPECIES", 124, 139], ["mice", "SPECIES", 302, 306], ["SARS-CoV-2", "SPECIES", 109, 119], ["Flu virus", "SPECIES", 200, 209], ["mice", "SPECIES", 302, 306], ["stained cells", "PROBLEM", 42, 55], ["\u0394NA(RBD)", "TEST", 56, 64], ["Flu", "PROBLEM", 65, 68], ["neutralizing antibodies", "TEST", 77, 100], ["SARS", "PROBLEM", 109, 113], ["CoV", "TEST", 114, 117], ["influenza virus", "PROBLEM", 124, 139], ["disease", "PROBLEM", 156, 163], ["the \u0394NA(RBD)", "PROBLEM", 187, 199], ["Flu virus", "PROBLEM", 200, 209], ["\u0394NA(RBD)", "TREATMENT", 366, 374], ["Flu", "TREATMENT", 375, 378], ["a control virus", "PROBLEM", 398, 413], ["a mock infection", "PROBLEM", 496, 512], ["stained cells", "OBSERVATION", 42, 55], ["NA segment", "ANATOMY", 436, 446], ["infection", "OBSERVATION", 503, 512]]], ["Mice were monitored for seven days post-infection for signs of illness, including reduced activity, ruffled fur, hunched posture, and weight loss (Fig 3B) .", [["illness", "DISEASE", 63, 70], ["weight loss", "DISEASE", 134, 145], ["Mice", "ORGANISM", 0, 4], ["Mice", "SPECIES", 0, 4], ["illness", "PROBLEM", 63, 70], ["reduced activity", "PROBLEM", 82, 98], ["ruffled fur", "PROBLEM", 100, 111], ["hunched posture", "PROBLEM", 113, 128], ["weight loss", "PROBLEM", 134, 145], ["ruffled fur", "OBSERVATION", 100, 111]]], ["No signs of disease or weight loss were observed in any group (Fig 3B) .", [["weight loss", "DISEASE", 23, 34], ["disease", "PROBLEM", 12, 19], ["weight loss", "PROBLEM", 23, 34], ["signs of", "UNCERTAINTY", 3, 11], ["disease", "OBSERVATION", 12, 19], ["weight loss", "OBSERVATION", 23, 34]]], ["We collected sera from the mice at 14-and 21-days post infection (dpi) and measured anti-SARS-CoV-2 titers using a Spike-pseudotyped lentivirus neutralization assay [33, 35] .", [["sera", "ANATOMY", 13, 17], ["sera", "ORGANISM_SUBSTANCE", 13, 17], ["mice", "ORGANISM", 27, 31], ["anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 84, 99], ["pseudotyped", "ORGANISM", 121, 132], ["lentivirus", "ORGANISM", 133, 143], ["anti-SARS", "PROTEIN", 84, 93], ["mice", "SPECIES", 27, 31], ["mice", "SPECIES", 27, 31], ["infection", "PROBLEM", 55, 64], ["anti-SARS", "TEST", 84, 93], ["CoV", "TEST", 94, 97], ["a Spike", "TEST", 113, 120], ["pseudotyped lentivirus neutralization assay", "TEST", 121, 164], ["infection", "OBSERVATION", 55, 64]]], ["Neutralizing responses against SARS-Cov-2 were detected in mice infected with the \u0394NA(RBD)-Flu at both 14and 21-dpi (Fig 3C, curves available in Suppl.", [["SARS-Cov-2", "GENE_OR_GENE_PRODUCT", 31, 41], ["mice", "ORGANISM", 59, 63], ["SARS-Cov-2", "DNA", 31, 41], ["mice", "SPECIES", 59, 63], ["mice", "SPECIES", 59, 63], ["SARS", "PROBLEM", 31, 35], ["Cov", "TEST", 36, 39], ["Flu", "PROBLEM", 91, 94]]], ["Three of the four mice in each dose group had neutralizing titers at 14 dpi, while all mice infected with \u0394NA(RBD)-Flu show neutralizing titers by 21 dpi (Fig 3C) .", [["mice", "ORGANISM", 18, 22], ["mice", "ORGANISM", 87, 91], ["mice", "SPECIES", 18, 22], ["mice", "SPECIES", 87, 91], ["mice", "SPECIES", 18, 22], ["mice", "SPECIES", 87, 91], ["neutralizing titers", "TREATMENT", 46, 65], ["Flu", "PROBLEM", 115, 118], ["neutralizing titers", "TEST", 124, 143]]], ["The neutralizing titers were higher for mice inoculated with a larger dose of \u0394NA(RBD)-Flu, although the difference was not statistically significant.", [["\u0394NA", "CHEMICAL", 78, 81], ["\u0394NA", "CHEMICAL", 78, 81], ["mice", "ORGANISM", 40, 44], ["\u0394NA", "SIMPLE_CHEMICAL", 78, 81], ["mice", "SPECIES", 40, 44], ["mice", "SPECIES", 40, 44], ["The neutralizing titers", "TEST", 0, 23], ["Flu", "PROBLEM", 87, 90]]], ["As expected, no neutralizing antibodies against SARS-CoV-2 Spike were detected in either the mock or \u0394NA(GFP)-Flu infected mice (Fig 3C) .", [["SARS-CoV-2", "ORGANISM", 48, 58], ["Spike", "GENE_OR_GENE_PRODUCT", 59, 64], ["\u0394NA", "GENE_OR_GENE_PRODUCT", 101, 104], ["GFP", "GENE_OR_GENE_PRODUCT", 105, 108], ["mice", "ORGANISM", 123, 127], ["neutralizing antibodies", "PROTEIN", 16, 39], ["mice", "SPECIES", 123, 127], ["SARS-CoV", "SPECIES", 48, 56], ["mice", "SPECIES", 123, 127], ["neutralizing antibodies", "TEST", 16, 39], ["SARS", "PROBLEM", 48, 52], ["CoV", "TEST", 53, 56], ["Spike", "PROBLEM", 59, 64], ["GFP", "TEST", 105, 108], ["Flu infected mice (Fig 3C", "TREATMENT", 110, 135], ["no", "UNCERTAINTY", 13, 15], ["neutralizing", "OBSERVATION_MODIFIER", 16, 28]]], ["These data indicate that a single intranasal inoculation with \u0394NA(RBD)-Flu induces rapid production of neutralizing antibodies against SARS-CoV-2.\u0394NA(RBD)-Flu induces neutralizing antibodies against SARS-CoV-2 and influenza virus without causing disease in miceFinally, we tested if the mice had also mounted an immune response to influenza virus.", [["\u0394NA", "CHEMICAL", 62, 65], ["Flu", "CHEMICAL", 71, 74], ["\u0394NA", "CHEMICAL", 146, 149], ["Flu", "CHEMICAL", 155, 158], ["influenza virus", "DISEASE", 214, 229], ["influenza virus", "DISEASE", 331, 346], ["Flu", "CHEMICAL", 71, 74], ["Flu", "CHEMICAL", 155, 158], ["SARS-CoV-2", "ORGANISM", 135, 145], ["\u0394NA", "SIMPLE_CHEMICAL", 146, 149], ["SARS-CoV-2", "ORGANISM", 199, 209], ["influenza virus", "ORGANISM", 214, 229], ["mice", "ORGANISM", 287, 291], ["influenza virus", "ORGANISM", 331, 346], ["neutralizing antibodies", "PROTEIN", 103, 126], ["RBD", "PROTEIN", 150, 153], ["neutralizing antibodies", "PROTEIN", 167, 190], ["CoV-2", "SPECIES", 204, 209], ["influenza virus", "SPECIES", 214, 229], ["mice", "SPECIES", 287, 291], ["SARS-CoV", "SPECIES", 135, 143], ["SARS-CoV-2", "SPECIES", 199, 209], ["influenza virus", "SPECIES", 214, 229], ["mice", "SPECIES", 287, 291], ["a single intranasal inoculation", "PROBLEM", 25, 56], ["\u0394NA(RBD)", "PROBLEM", 62, 70], ["Flu", "PROBLEM", 71, 74], ["neutralizing antibodies", "TEST", 103, 126], ["SARS", "PROBLEM", 135, 139], ["CoV", "TEST", 140, 143], ["\u0394NA(RBD)", "TEST", 146, 154], ["Flu", "PROBLEM", 155, 158], ["neutralizing antibodies", "TEST", 167, 190], ["SARS", "PROBLEM", 199, 203], ["CoV", "TEST", 204, 207], ["influenza virus", "PROBLEM", 214, 229], ["disease in miceFinally", "PROBLEM", 246, 268], ["influenza virus", "PROBLEM", 331, 346], ["influenza virus", "OBSERVATION", 331, 346]]], ["We performed influenza virus neutralization assays with blood collected at 21 dpi, using an influenza virus with the H3 from A/Aichi/2/1968 with Y98F and G379W mutations (the same mutations present in the HA \u0394NA(RBD)-Flu).", [["blood", "ANATOMY", 56, 61], ["blood", "ORGANISM_SUBSTANCE", 56, 61], ["A/Aichi", "ORGANISM", 125, 132], ["Y98F", "GENE_OR_GENE_PRODUCT", 145, 149], ["G379W", "GENE_OR_GENE_PRODUCT", 154, 159], ["RBD", "PROTEIN", 212, 215], ["influenza virus", "SPECIES", 92, 107], ["influenza virus", "SPECIES", 92, 107], ["A/Aichi/2/1968", "SPECIES", 125, 139], ["influenza virus neutralization assays", "TREATMENT", 13, 50], ["an influenza virus", "PROBLEM", 89, 107], ["G379W mutations", "PROBLEM", 154, 169], ["the same mutations", "PROBLEM", 171, 189]]], ["As expected, high levels of neutralizing antibodies against influenza virus were present in mice infected with either \u0394NA(RBD)-Flu or \u0394NA(GFP)-Flu (Fig 3D) .DiscussionHere we describe an engineered influenza virus, \u0394NA(RBD)-Flu, that expresses a membraneanchored form of SARS-CoV-2 Spike RBD from its NA segment.", [["influenza virus", "DISEASE", 60, 75], ["influenza virus", "DISEASE", 198, 213], ["SARS", "DISEASE", 271, 275], ["\u0394NA", "CHEMICAL", 134, 137], ["Flu", "CHEMICAL", 143, 146], ["influenza virus", "ORGANISM", 60, 75], ["mice", "ORGANISM", 92, 96], ["influenza virus", "ORGANISM", 198, 213], ["neutralizing antibodies", "PROTEIN", 28, 51], ["RBD", "PROTEIN", 122, 125], ["SARS-CoV-2 Spike RBD", "PROTEIN", 271, 291], ["NA segment", "DNA", 301, 311], ["influenza virus", "SPECIES", 60, 75], ["mice", "SPECIES", 92, 96], ["influenza virus", "SPECIES", 198, 213], ["influenza virus", "SPECIES", 60, 75], ["mice", "SPECIES", 92, 96], ["neutralizing antibodies", "TREATMENT", 28, 51], ["influenza virus", "PROBLEM", 60, 75], ["Flu", "PROBLEM", 127, 130], ["\u0394NA", "PROBLEM", 134, 137], ["GFP", "TEST", 138, 141], ["an engineered influenza virus", "PROBLEM", 184, 213], ["Flu", "PROBLEM", 224, 227], ["SARS", "PROBLEM", 271, 275], ["CoV", "TEST", 276, 279], ["Spike RBD", "PROBLEM", 282, 291], ["NA segment", "ANATOMY_MODIFIER", 301, 311]]], ["The \u0394NA(RBD)-Flu virus stably maintains the gene encoding the RBD over multiple passages, and cells infected with this virus express high levels of RBD on their surface.", [["cells", "ANATOMY", 94, 99], ["surface", "ANATOMY", 161, 168], ["\u0394NA", "GENE_OR_GENE_PRODUCT", 4, 7], ["RBD", "GENE_OR_GENE_PRODUCT", 62, 65], ["cells", "CELL", 94, 99], ["RBD", "GENE_OR_GENE_PRODUCT", 148, 151], ["surface", "CELLULAR_COMPONENT", 161, 168], ["RBD", "PROTEIN", 8, 11], ["RBD", "PROTEIN", 62, 65], ["RBD", "PROTEIN", 148, 151], ["Flu virus", "SPECIES", 13, 22], ["The \u0394NA(RBD", "PROBLEM", 0, 11], ["Flu virus", "PROBLEM", 13, 22], ["cells infected", "PROBLEM", 94, 108], ["this virus", "PROBLEM", 114, 124], ["RBD", "OBSERVATION", 148, 151]]], ["Intranasal inoculation of mice with a single dose of \u0394NA(RBD)-Flu elicits neutralizing antibodies against SARS-CoV-2 in mice, with titers comparable to those observed in humans following natural infection [33, 43, 44] or administration of two doses of a mRNA-based vaccine in clinical trials [20] .", [["\u0394NA", "CHEMICAL", 53, 56], ["Flu", "CHEMICAL", 62, 65], ["natural infection", "DISEASE", 187, 204], ["mice", "ORGANISM", 26, 30], ["\u0394NA", "SIMPLE_CHEMICAL", 53, 56], ["SARS-CoV-2", "ORGANISM", 106, 116], ["mice", "ORGANISM", 120, 124], ["humans", "ORGANISM", 170, 176], ["neutralizing antibodies", "PROTEIN", 74, 97], ["mice", "SPECIES", 26, 30], ["mice", "SPECIES", 120, 124], ["humans", "SPECIES", 170, 176], ["mice", "SPECIES", 26, 30], ["SARS-CoV", "SPECIES", 106, 114], ["mice", "SPECIES", 120, 124], ["humans", "SPECIES", 170, 176], ["\u0394NA(RBD", "TREATMENT", 53, 60], ["Flu elicits neutralizing antibodies", "TEST", 62, 97], ["SARS", "PROBLEM", 106, 110], ["CoV", "TEST", 111, 114], ["titers", "PROBLEM", 131, 137], ["natural infection", "PROBLEM", 187, 204], ["a mRNA-based vaccine", "TREATMENT", 252, 272], ["infection", "OBSERVATION", 195, 204]]], ["Notably, the \u0394NA(RBD)-Flu elicited these neutralizing antibody titers after just a single intranasal inoculation at a viral dose that is lower than that typically used for live-attenuated influenza vaccines [4, 13, 45] .", [["Flu", "CHEMICAL", 22, 25], ["influenza", "DISEASE", 188, 197], ["Flu", "CHEMICAL", 22, 25], ["RBD", "PROTEIN", 17, 20], ["the \u0394NA(RBD)", "PROBLEM", 9, 21], ["Flu", "PROBLEM", 22, 25], ["these neutralizing antibody titers", "PROBLEM", 35, 69], ["a single intranasal inoculation", "TREATMENT", 81, 112], ["a viral dose", "TREATMENT", 116, 128], ["live-attenuated influenza vaccines", "TREATMENT", 172, 206]]], ["It therefore seems possible that neutralizing antibody titers against SARS-CoV-2 could be further enhanced by using a higher viral dose in a single inoculation, and/or by boosting either with recombinant RBD or a second administration of a \u0394NA(RBD)-Flu variant containing a different HA protein.DiscussionOur study also has several important limitations.", [["SARS", "DISEASE", 70, 74], ["SARS-CoV-2", "ORGANISM", 70, 80], ["recombinant RBD", "PROTEIN", 192, 207], ["RBD", "PROTEIN", 244, 247], ["Flu variant", "PROTEIN", 249, 260], ["HA protein", "PROTEIN", 284, 294], ["SARS-CoV", "SPECIES", 70, 78], ["neutralizing antibody titers", "TEST", 33, 61], ["SARS", "PROBLEM", 70, 74], ["CoV", "TEST", 75, 78], ["a higher viral dose", "TREATMENT", 116, 135], ["a single inoculation", "TREATMENT", 139, 159], ["recombinant RBD", "PROBLEM", 192, 207], ["a \u0394NA(RBD", "PROBLEM", 238, 247], ["Flu variant", "PROBLEM", 249, 260], ["a different HA protein", "TREATMENT", 272, 294], ["DiscussionOur study", "TEST", 295, 314], ["seems possible", "UNCERTAINTY", 13, 27]]], ["First, we examined the effect of \u0394NA(RBD)-Flu vaccination only in influenza-na\u00efve mice.", [["\u0394NA", "CHEMICAL", 33, 36], ["Flu", "CHEMICAL", 42, 45], ["influenza-na\u00efve", "DISEASE", 66, 81], ["\u0394NA", "CHEMICAL", 33, 36], ["Flu", "CHEMICAL", 42, 45], ["\u0394NA", "SIMPLE_CHEMICAL", 33, 36], ["mice", "ORGANISM", 82, 86], ["mice", "SPECIES", 82, 86], ["mice", "SPECIES", 82, 86], ["\u0394NA(RBD", "PROBLEM", 33, 40], ["Flu vaccination", "TREATMENT", 42, 57], ["influenza", "PROBLEM", 66, 75]]], ["For other live attenuated vaccines, pre-existing immunity against the vaccine vector (influenza virus, in this case) can reduce effectiveness [46, 47] .", [["influenza virus", "DISEASE", 86, 101], ["influenza virus", "ORGANISM", 86, 101], ["influenza virus", "SPECIES", 86, 101], ["other live attenuated vaccines", "TREATMENT", 4, 34], ["pre-existing immunity", "TREATMENT", 36, 57], ["the vaccine vector", "TREATMENT", 66, 84], ["influenza virus", "PROBLEM", 86, 101]]], ["This limitation could potentially be overcome by creating variants of \u0394NA(RBD)-Flu that contain HA subtypes to which the human population is na\u00efve, although we did not attempt that here.", [["\u0394NA", "GENE_OR_GENE_PRODUCT", 70, 73], ["human", "ORGANISM", 121, 126], ["RBD", "PROTEIN", 74, 77], ["human", "SPECIES", 121, 126], ["human", "SPECIES", 121, 126], ["\u0394NA(RBD)", "PROBLEM", 70, 78], ["Flu", "PROBLEM", 79, 82], ["HA subtypes", "PROBLEM", 96, 107], ["could potentially be", "UNCERTAINTY", 16, 36], ["HA subtypes", "OBSERVATION_MODIFIER", 96, 107]]], ["Second, we performed experiments using only in a single strain of mice (BALB/cJ) and have not examined the results of vaccination with \u0394NA(RBD)-Flu in non-human primates or other animal models.", [["BALB/cJ", "ANATOMY", 72, 79], ["\u0394NA", "CHEMICAL", 135, 138], ["Flu", "CHEMICAL", 144, 147], ["mice", "ORGANISM", 66, 70], ["BALB/cJ", "ORGANISM", 72, 79], ["\u0394NA", "SIMPLE_CHEMICAL", 135, 138], ["non-human", "ORGANISM", 151, 160], ["primates", "ORGANISM", 161, 169], ["mice", "SPECIES", 66, 70], ["mice", "SPECIES", 66, 70], ["Flu", "PROBLEM", 144, 147]]], ["Third, although the \u0394NA(RBD)-Flu grew to reasonably high titers that were sufficient for our experiments, the titers were still lower than those obtained using virus with an intact NA segment.", [["\u0394NA", "GENE_OR_GENE_PRODUCT", 20, 23], ["RBD", "PROTEIN", 24, 27], ["the \u0394NA(RBD", "TEST", 16, 27], ["Flu", "PROBLEM", 29, 32], ["high titers", "PROBLEM", 52, 63], ["the titers", "TEST", 106, 116], ["virus", "TREATMENT", 160, 165], ["intact", "OBSERVATION", 174, 180], ["NA segment", "OBSERVATION", 181, 191]]], ["Fourth, although we demonstrated high SARS-CoV-2 neutralizing antibody titers at three weeks post vaccination, we did not perform experiments to examine the durability of these titers over longer timeframes.", [["CoV-2", "GENE_OR_GENE_PRODUCT", 43, 48], ["high SARS", "PROBLEM", 33, 42], ["CoV", "TEST", 43, 46], ["2 neutralizing antibody titers", "PROBLEM", 47, 77], ["vaccination", "TREATMENT", 98, 109], ["high", "OBSERVATION_MODIFIER", 33, 37], ["SARS", "OBSERVATION", 38, 42]]], ["Finally, while the presence of neutralizing titers against SARS-CoV-2 is correlated with protection against infection in animal models [48, 49] and preliminarily in human studies [50] , we did not directly test if the neutralizing antibodies elicited by \u0394NA(RBD)-Flu are protective against viral challenge.DiscussionDespite these limitations, vaccines based on \u0394NA(RBD)-Flu have several possible advantages.", [["SARS", "DISEASE", 59, 63], ["infection", "DISEASE", 108, 117], ["Flu", "CHEMICAL", 263, 266], ["SARS-CoV-2", "ORGANISM", 59, 69], ["human", "ORGANISM", 165, 170], ["neutralizing antibodies", "PROTEIN", 218, 241], ["RBD", "PROTEIN", 258, 261], ["human", "SPECIES", 165, 170], ["SARS-CoV", "SPECIES", 59, 67], ["human", "SPECIES", 165, 170], ["neutralizing titers", "TEST", 31, 50], ["SARS", "PROBLEM", 59, 63], ["infection", "PROBLEM", 108, 117], ["human studies", "TEST", 165, 178], ["the neutralizing antibodies", "TEST", 214, 241], ["Flu", "PROBLEM", 263, 266], ["viral challenge", "TREATMENT", 290, 305], ["vaccines", "TREATMENT", 343, 351], ["Flu", "PROBLEM", 370, 373]]], ["First, the vaccine induces neutralizing antibodies with a just single dose.", [["neutralizing antibodies", "PROTEIN", 27, 50], ["the vaccine", "TREATMENT", 7, 18], ["neutralizing antibodies", "TREATMENT", 27, 50]]], ["Second, live influenza viruses induce mucosal immune responses [10, 13, 15, 51] that may be important for protective immunity to SAR-CoV-2 [17, 52] .", [["mucosal", "ANATOMY", 38, 45], ["influenza viruses", "DISEASE", 13, 30], ["live influenza viruses", "ORGANISM", 8, 30], ["mucosal", "PATHOLOGICAL_FORMATION", 38, 45], ["SAR-CoV-2", "ORGANISM", 129, 138], ["live influenza viruses", "PROBLEM", 8, 30], ["CoV", "TEST", 133, 136]]], ["Third, it might be possible to leverage additional influenza-virusengineering approaches such as those described in [11] to generate virions that express NA as well as RBD, and could serve as dual influenza-and SARS-CoV-2 vaccines.", [["virions", "ANATOMY", 133, 140], ["SARS-CoV-2", "ORGANISM", 211, 221], ["RBD", "PROTEIN", 168, 171], ["influenza", "PROBLEM", 51, 60], ["virusengineering approaches", "TREATMENT", 61, 88], ["RBD", "PROBLEM", 168, 171], ["dual influenza", "PROBLEM", 192, 206], ["SARS", "PROBLEM", 211, 215], ["CoV-2 vaccines", "TREATMENT", 216, 230], ["might be possible", "UNCERTAINTY", 10, 27], ["influenza", "OBSERVATION", 51, 60]]], ["Finally, a major challenge to rapid development and deployment of a vaccine for COVID-19 is scaling production in order to distribute a large number of doses worldwide.", [["COVID-19", "CHEMICAL", 80, 88], ["a vaccine", "TREATMENT", 66, 75], ["COVID", "TEST", 80, 85], ["scaling production", "PROBLEM", 92, 110], ["large", "OBSERVATION_MODIFIER", 136, 141], ["number", "OBSERVATION_MODIFIER", 142, 148]]], ["There is already existing infrastructure for large-scale production of influenza-virus based vaccines which could in principle be extended to also produce live-virus vaccines similar to \u0394NA(RBD)-Flu at scale [23] .PatentsA.N.L., L.E.G., A.J.G., and J.D.B are listed as inventors on a provisional patent application based on the studies presented in this paper.", [["influenza-virus", "ORGANISM", 71, 86], ["live-virus", "ORGANISM", 155, 165], ["influenza-virus", "SPECIES", 71, 86], ["influenza-virus", "SPECIES", 71, 86], ["large-scale production", "TREATMENT", 45, 67], ["influenza-virus based vaccines", "TREATMENT", 71, 101], ["live-virus vaccines", "TREATMENT", 155, 174], ["a provisional patent application", "TREATMENT", 282, 314], ["the studies", "TEST", 324, 335], ["infrastructure", "OBSERVATION", 26, 40], ["large", "OBSERVATION_MODIFIER", 45, 50], ["-scale", "OBSERVATION_MODIFIER", 50, 56], ["patent", "OBSERVATION", 296, 302]]]], "7717f7d8ade71f266f77a3c19bfba2e668904aaa": [["including insecticide-treated bed nets and effective case management [1, 2] .", [["effective case management", "TREATMENT", 43, 68]]], ["Long-lasting insecticide treated bed nets (LLINs) and indoor residual spraying (IRS) as vector control interventions have made major contributions towards the recent gains [3, 4] .", [["indoor residual spraying (IRS)", "TREATMENT", 54, 84], ["vector control interventions", "TREATMENT", 88, 116]]], ["Despite these gains, malaria still remains a major public health problem in Africa as reported by stable or increasing incidence rates over the past few years in many African countries [1] .", [["malaria", "DISEASE", 21, 28], ["malaria", "PROBLEM", 21, 28], ["increasing incidence rates", "PROBLEM", 108, 134], ["malaria", "OBSERVATION", 21, 28], ["stable", "OBSERVATION_MODIFIER", 98, 104]]], ["Development of resistance to drugs [5] and insecticides [6, 7] in the malaria parasites and vectors, respectively, and vector behavioural plasticity, such as outdoor feeding and resting [8] , threaten the efficacy of available interventions to reduce the malaria burden.", [["[5] and insecticides [6, 7]", "CHEMICAL", 35, 62], ["malaria", "DISEASE", 70, 77], ["malaria", "DISEASE", 255, 262], ["resistance to drugs", "TREATMENT", 15, 34], ["vector behavioural plasticity", "TREATMENT", 119, 148], ["available interventions", "TREATMENT", 217, 240], ["the malaria burden", "PROBLEM", 251, 269], ["resistance", "OBSERVATION", 15, 25], ["malaria", "OBSERVATION", 255, 262]]]]}